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Abstract: Gynecological cancers pose an important public health issue, with a high incidence among
women of all ages. Gynecological cancers such as malignant germ-cell tumors, sex-cord-stromal
tumors, uterine sarcomas and carcinosarcomas, gestational trophoblastic neoplasia, vulvar carci-
noma and melanoma of the female genital tract, are defined as rare with an annual incidence of
<6 per 100,000 women. Rare gynecological cancers (RGCs) are associated with poor prognosis, and
given the low incidence of each entity, there is the risk of delayed diagnosis due to clinical inexperi-
ence and limited therapeutic options. There has been a growing interest in the field of microRNAs
(miRNAs), a class of small non-coding RNAs of ∼22 nucleotides in length, because of their potential
to regulate diverse biological processes. miRNAs usually induce mRNA degradation and transla-
tional repression by interacting with the 3′ untranslated region (3′-UTR) of target mRNAs, as well as
other regions and gene promoters, as well as activating translation or regulating transcription under
certain conditions. Recent research has revealed the enormous promise of miRNAs for improving the
diagnosis, therapy and prognosis of all major gynecological cancers. However, to date, only a few
studies have been performed on RGCs. In this review, we summarize the data currently available
regarding RGCs.
Keywords: rare gynecological cancers; microRNAs; miRNAs; cancer stem cells; circulating biomark-
ers; extracellular vesicles; microRNA-based therapy
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1. Introduction
Gynecological cancers are cancers that arise in the female reproductive organs, en-
compassing ovarian, fallopian tubal, uterine/endometrial, cervical, vaginal and vulval
cancers, and gestational trophoblastic disease [1]. Each gynecological cancer has its own
signs, symptoms and risk factors. Gynecological cancers pose an important public health
issue, with a high incidence among women of all ages [2]. Patients are often diagnosed at
a late stage. This could be due to several reasons including lack of awareness of specific
differential symptoms, improper screening and even misdiagnosis [3]. Late diagnosis,
combined with limited treatment options for advanced gynecological cancers are major
contributing factors to the high mortality, thus emphasizing the need for further advance-
ment in the area. These issues are further exacerbated in the case of rare gynecological
cancers (RGCs) [4].
Many gynecological cancers, for example malignant germ-cell tumors, sex cord-
stromal tumors, gestational trophoblastic neoplasia, vaginal/vulvar carcinoma, and
melanoma of the female genital tract, are uncommon and have different clinicopatho-
logical characteristics, thus implicating diverse molecular biological pathogeneses. These
tumors are defined as “rare”, with an annual incidence of <6 per 100,000 women and cumu-
latively account for over 50% of gynecological cancers [5–8]. RGCs are generally associated
with poor prognosis. Since these cancers are rare, patient management becomes difficult
in terms of correct diagnosis and limited therapy options, and given the low incidence of
each disease, this poses a major hurdle in the management of patients.
The field of miRNAs has been increasingly investigated because of their potential role
in the regulation of different biological processes [9]. miRNAs are a class of non-coding
RNAs that are approximately 20–22 nucleotides in length, and are involved in the regulation
of gene expression. Usually, miRNAs induce mRNA degradation and/or translational
repression by interacting with the 3′ untranslated region (3′-UTR) of target mRNAs. There
are few cases of miRNAs interacting with different regions on genes including promoters.
They have also been reported to be involved in the or activation of and regulation of gene
transcription [10]. According to the latest miRbase [11], 38,589 hairpin precursors and
48,860 mature miRNAs have been reported for nearly 300 organisms. For the human
genome, the current numbers are 1917 annotated hairpin precursors, and 2654 mature
sequences [11]. Given the rate of discovery of new miRNAs, it is predicted that, in fact,
miRNAs may regulate the expression of almost one-third of all human genes [12].
Recent research has revealed the enormous promise for miRNAs to improve the
diagnosis, and management of all major gynecological cancers (cervical, endometrial and
ovarian cancers) [1]. This is backed up by research on miRNAs in other cancers such as
thyroid, breast and gastric cancer [13–15]. Numerous miRNAs are believed to influence
multiple biological functions, leading to modulation of the tumor microenvironment,
including stemness, growth, proliferation, invasion and metastasis [1]. In addition, miRNA
signatures have been proposed as potential biomarkers that can be used for early detection
of gynecological cancers, as well as predictors of response to ongoing therapies [1]. Based
on the available and emerging data, miRNAs could impact future therapeutic strategies for
ovarian, cervical, and endometrial carcinomas.
Almost 15 years have passed since the first publication on the aberrant expression of
miRNAs in human epithelial ovarian cancer [16]. However, to date, only a few studies
have been performed on RGCs. In this review, we summarize the data currently available,
in order to assess the progress made to date.
2. Biogenesis and Function of miRNAs
In the search for novel diagnostic and therapeutic targets for cancer, miRNAs have
become of significant interest, particularly because of their abundance and potential ease
of detection in both tissue and plasma, and therefore they represent potential non-invasive
molecular markers for cancer diagnosis and therapeutic response. miRNA biogenesis
is a multi-step process that starts in the nucleus (Figure 1) [17–20]. Here, miRNAs are
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generally transcribed by RNA Polymerase II into long primary transcripts (pri-miRNA)
that are further processed in the nucleus by Drosha/DGCR8 to form an intermediate
structure called the pre-miRNA (precursor), made up of 60-70 nucleotides [17,21,22]. The
nuclear export factor Exportin-5/Ran-GTP carries the pre-miRNA to the cytoplasm where,
following a series of excisions by RNase III endonuclease, Dicer/TRBP and Ago2, a mature
17–25 bp miRNA duplex is generated. A helicase unwinds this miRNA duplex to form
a mature single-stranded miRNA, which enters into the RNA-induced silencing complex
(RISC). At this point, the complex is directed to target mRNA. It is thought that mature
miRNAs regulate gene expression through the binding to the 3′ UTR of target mRNA,
thus degrading mRNA or inhibiting translation. In the presence of distinct cofactors and
conditions, miRNAs may be capable of activating gene expression directly or indirectly
in response to different cell types [10,23,24]. Thus, this process allows the cell to respond
rapidly to different cellular conditions due to the reversibility in their post-translational
gene regulation. In addition, cells can produce miRNAs via several non-canonical processes.
Some miRNA-like species, such as a subclass termed agotrons, are capable of bypassing
particular steps of the canonical miRNA biogenesis pathway, escaping both Drosha and
Dicer processing [25].
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3. miRNAs as Novel Therapeutic Strategies
The link between cancer and miRNAs was first reported almost two decades
ago [26,27]. Studies in numerous human cancers have since confirmed that miRNAs
are often associated with sites of chromosomal amplification or instability [28]. The aber-
rant expression of miRNAs has been linked to the stage, progression and metastasis of a
wide variety of tumors [28,29]. In fact, miRNAs can function as tumor suppressors (TsmiRs)
or tumor promoters (OncomiRs) [30,31]. In addition, miRNAs have also been shown to be
involved in cancer stem cells (CSCs) and epithelial–mesenchymal transition (EMT), which
Int. J. Mol. Sci. 2021, 22, 3822 4 of 26
are largely responsible for drug resistance and cancer metastasis [1,29]. Hence, targeting
miRNAs holds the promise of being an effective option in the management of cancer,
with possible therapeutic approaches including achieving “gain” or “loss” of miRNA
functions in the tumor cells (Figure 2) [32]. For example, restoring the expression of tumor-
suppressive miRNAs may be therapeutically beneficial [32]. In fact, synthetic miRNA
mimics have already been used to restore the function of miRNAs in cancer cells [33]. In
contrast, several approaches have been applied to achieve the downregulation of oncogenic
miRNAs, including the use of miRNA sponges, small molecule inhibitors, anti-miRNA
oligonucleotides (AMOs) and miRNA masking [34–36]. Overall, restoration or silencing
of miRNA function is a promising strategy for cancer treatment. Furthermore, since miR-
NAs are also involved in radio- and chemo-sensitization of cancer cells, a combination of
approaches may be developed for improved therapeutic outcome [37].
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Figure 2. miRNA-based therapeutic intervention in cancer. Through inhibition of oncogenic miRNAs (Oncomirs), miRNA
expression is modulated using small molecule inhibitors, anti-miR oligonucleotides (AMOs), miRNA masks/target protec-
tors or miRNA sponges, or by reconstituting tumor suppressor miRNAs (TsmiRs), through delivery of miRNA mimics or
gene therapy. BioRender has been used to create parts of this figure. (https://biorender.com, accessed on 26 March 2021).
However, to date, there are several challenges that need to be overcome before
miRNAs can actually be used as therapeutic agents. In fact, RNA oligonucleotides have cer-
tain features that complicate drug design and efficacy. Initial hurdles are RNA degradation
by nucleases upon addition into biological systems and poor cell membrane penetration.
These can potentially be dealt with by undertaking chemical modifications to the oligonu-
cleotides, and using different delivery systems (e.g., liposomes, polymers, exosomes) to
make up for their hydrophilic characteristics, negative charge and high molecular weight,
which usually block nucleic acids from penetrating the cell membrane [38]. Other chal-
lenges include entrapment in the endosome, poor binding affinity for complementary
sequences, poor delivery to desired target tissues; activation of innate immune responses
and, last but not least, off-target and unwanted toxicities.
4. Dysregulation of miRNAs in Rare Gynecological Cancers
Emerging evidence demonstrates dysregulation of various miRNAs in gynecological
cancers, suggesting pathobiological relevance [1]. Here, we highlight the ongoing chal-
lenges associated with the early diagnosis and effective treatment of specific RGCs and
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discuss how miRNAs may further improve the diagnostic, prognostic and therapeutic
strategies for these tumor types (Table 1).












































































































































































Ovarian cancer is the leading cause of death in women who are diagnosed with
gynecological cancer, and overall, it is the fifth most frequent cause of death in women.
Ovarian cancer is divided into epithelial and non-epithelial subgroups. Epithelial ovarian
cancer is classified according to histopathological appearance and clinical behavior and
includes serous (low and high grade), clear cell, mucinous, endometrioid, carcinosarcoma
and also fallopian tube and primary peritoneal cancer [39]. Non-epithelial ovarian tumors
are relatively rare, but in total, they still account for approximately 10% of all ovarian
malignancies. These are challenging from a diagnosis and management point of view,
due to their rarity. Non-epithelial tumors include a large variety of different pathological
types, including mesenchymal tumors (low- and high-grade endometrioid stromal tumors),
mixed epithelial and stromal tumors (adenosarcomas and carcinosarcomas), pure stromal
tumors (e.g., fibromas and thecomas), pure sex cord-stromal tumors (e.g., adult granulosa
cell tumors and juvenile granulosa cell tumors), mixed-sex cord-stromal tumors (e.g.,
Sertoli–Leydig cell tumors) and germ cell tumors [40].
4.1.1. miRNAs in the Rare Types of Epithelial Ovarian Cancers
Epithelial ovarian cancer is the most common group of ovarian cancer, however, it
also includes the rare clear-cell, mucinous and low-grade serous carcinoma types [41].
High-grade serous carcinomas (which are not rare) almost always arise from the tube, and
there is some evidence that low-grade serous carcinomas also do. Most of these types
present at a low stage (by contrast with high-grade serous carcinoma) but they do on
occasion present at a high stage. Especially when the diagnosis is at a late stage, although
the initial treatment might possibly lead to a complete response, relapse is common with
minimal response to chemotherapy [42].
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Ovarian clear cell cancer (OCCC) diagnosed at an earlier stage tends to have a good
prognosis as surgery is often curative. In advanced stages, however, it is more likely to
be resistant to chemotherapy and has a worse prognosis. Due to the relative rarity of
OCCC, there have been limited efforts in improving outcomes [4]. Similarities in molecular
pathways exist among OCCC and clear-cell carcinoma of the kidney [43], where inhibition
of angiogenesis, growth-factor signaling and mTOR pathways, might improve survival.
Treatments that are used in the case of clear-cell carcinoma of the kidney, such as multiki-
nase inhibitors (sunitinib, axitinib, sorafenib and pazopanib), temsirolimus, bevacizumab,
and everolimus might have anti-tumor activity in OCCC, although preliminary clinical
data from studies focusing only on OCCC are limited [44].
Loss of ARID1A and activation of PIK3CA are the most common somatic genetic
alterations in OCCC (66.7% and 50% respectively), followed by mutations in PPP2R1A
(18.8%) and KRAS (16.7%) [45]. Inhibition of the methyltransferase EZH2 and the adminis-
tration of dasatinib and/or the HDAC6 inhibitor ACY1215 may represent novel treatment
strategies for ARID1A mutated OCCC [46–48]. It has been shown that ARID1A-mutated
OCCC cells have a specific sensitivity to small molecule inhibitors of the bromodomain
and extra terminal domain (BET) family of proteins, to which BRD2 belongs, and which
in turn causes a reduction in the expression of multiple SWI/SNF members including
ARID1B [49].
EGFR inhibitors might be effective therapeutic agents, given that EGFR expression
is detected in up to 60% of OCCCs [50]. In addition, high expression of mTOR has been
reported in both early- and advanced-stage OCCC, with mTOR inhibitors being promising
agents for treatment, especially in recurrent OCCC with cisplatin resistance [51].
Primary mucinous epithelial ovarian cancer (mEOC) accounts for less than 5% of
epithelial ovarian cancers, with a decreasing incidence due to the fact that many cases that
were previously diagnosed as primary mEOCs were actually metastases from other organs,
mostly from the gastrointestinal tract. This highlights the importance of clinico-pathological
review, because the pathology does not necessarily distinguish between primary and
metastatic mucinous carcinomas, particularly if they have an upper GI phenotype. While
it is recommended to treat mEOC with adjuvant carboplatin and paclitaxel, in-depth
molecular characterization of mEOC suggests that trastuzumab (Herceptin) and HER2-
targeted therapies might be an effective treatment as HER2 is amplified or expressed in
19% [52] or 18.2% of these tumors [4], respectively.
Therefore, in order to improve prognosis through the development of a more specific
treatment, thereby improving prognosis improved insight into the molecular characteristics
of the different epithelial ovarian cancer subgroups. Several miRNAs, such as miR-509-3-5p,
miR-509-3p, miR-509-5p, and miR-510, are differentially expressed in OCCC, high-grade
serous ovarian carcinoma (HGSC) and ovarian surface epithelium (OSE), suggesting a
carcinogenic role [53]. Furthermore, miR-424 has the capacity to suppress cell invasion and
EMT in OCCC through downregulation of DCLK1, thus suggesting potential therapeutic
targets [54]. Yanaihara et al. found higher levels of miR-9, miR-34a and miR-126 in OCCC,
compared to HGSC [55]. Moreover, miR-9 overexpression may affect pathogenesis in
OCCC by targeting E-cadherin and inducing EMT. In addition, it has been shown that
miR-449 is under-expressed in OCCC [56] and that miR-29b signaling is involved in the
sensitivity to chemotherapy in these cases [57]. Finally, Agostini et al. found that miR-192,
miR-194, and miR-215 are upregulated in mEOC, suggesting that the miR192/215 family
miRNAs may exert oncogenic functions in this tumor type [58].
4.1.2. miRNAs in Nonepithelial Ovarian Cancers
Nonepithelial ovarian cancers including malignant germ-cell tumors and sex-cord
stromal tumors are very rare and account for only 6% of all ovarian malignancies [59–62].
Malignant germ-cell tumors occur more commonly among women below 20 years of
age and are often treated as their testicular counterparts. These tumors can be histologically
classified as immature teratoma, dysgerminoma, yolk sac tumor, embryonal carcinoma,
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choriocarcinoma, mixed germ-cell tumor, malignant struma ovarii, teratoma with malig-
nant transformation and gonadoblastoma [63]. Nowadays, with the use of platinum-based
regimens, the five-year overall survival (OS) is estimated to be over 90% for early-stage
tumors and above 75% for advanced disease [60]. The role of adjuvant chemotherapy is
well established, with regimens such as BEP (bleomycin, etoposide, and cisplatin) being
in routine use. However, in the case of relapsed ovarian germ-cell tumors, to date, there
are no trials to suggest the benefits of a second-line therapy or the utility of high-dose
chemotherapy to be followed by autologous stem cell transplant, as in testicular germ-cell
tumors. Current practices include the use of TIP (paclitaxel, ifosfamide, and cisplatin),
with extrapolation from treatment used for testicular germ-cell tumors, and even using
more complex regimens containing combinations of cisplatin, methotrexate, bleomycin
and vincristine, alternating with cyclophosphamide, actinomycin D, and etoposide [59].
Furthermore, targeted therapies that have been investigated consist of tyrosine kinase in-
hibitors (TKIs) (i.e., imatinib and sunitinib), trastuzumab (anti-HER2 monoclonal antibody)
and antiangiogenic agents such as thalidomide and bevacizumab [64].
Granulosa cell tumors are a common type of malignant sex-cord stromal tumor and
constitute about 5% of malignant ovarian tumors. There are two main distinct types: adult-
type and juvenile granulosa cell tumors, which are different tumor types, but most data
refer to adult-type tumors. Sertoli-Leydig cell tumors, steroid cell tumors, gynandroblas-
tomas, and sex cord tumors with annular tubules are infrequently detected. Histologically,
granulosa cell tumors are composed of granulosa cells, which secrete progesterone and
estrogen [64]. Testing for the C134W FOXL2 mutation is helpful in the diagnosis of adult-
type tumors where the morphological appearances are not characteristic [65]. Granulosa
cell tumors tend to have a slow progression and late recurrence.
In the case of women with advanced-stage or recurrent granulosa cell tumor, there
is limited effectiveness of traditional chemotherapy [66]. The ongoing GOG264 trial
(NCT01042522) is currently comparing the efficacy of carboplatin and paclitaxel versus
(BEP) in advanced or recurrent sex cord-ovarian stromal cell tumors. Furthermore, targeted
therapies such as vascular endothelial growth factor (VEGF) inhibitors, TKIs, and hormonal
treatment have been investigated as therapeutic options for granulosa cell tumors [4].
Molecular pathogenesis of these tumor types is starting to be unraveled, especially in
relation to the role of FOXL2 [67]. Chang et al. characterized miRNA expression profiles
of some germ-cell tumors and sex cord-stromal tumors using small RNA sequencing [68].
Higher expression of miR-302c-3p, miR-372-3p and miR-373-3p, and lower expression
of miR-199a-5p, miR-202-3p and miR-214-5p have been observed in malignant germ-cell
tumors when compared to benign germ-cell tumors or sex-cord stromal tumors. In sex-cord
stromal tumors, miR-513c-5p and miR-202c-3p were more abundant than in benign germ-
cell tumors. Additionally, expression of Beclin 1 (BECN1), which is a target of miR-199a-5p,
was shown to be higher in malignant germ-cell tumors than benign germ-cell tumors,
which corresponds with their lower expression of miR-199a-5p.
Poynter et al. analyzed molecular signatures in dysgerminoma and yolk sac tumor,
compared to adjacent tissue samples [69]. Differences in miRNA expression were observed,
with miR-122, miR-302a, miR-302d, miR-371-5p and miR-373 showing elevated expression
in one or more histologic subtypes. Correlations were also identified across six major
hubs with higher expression in yolk sac tumor (miR-302b, miR-302a, miR-122 and miR 126;
LEFTY1 and LEFTY2) compared with other germ-cell tumors. Cheng et al. validated
six miRNAs (miR-29c-3p, miR-138-5p, miR-184, miR-204-5p, miR-328-3p and miR-501-3p)
as novel markers for subtype classification in ovarian granulosa cell tumors with low levels
of miR-138-5p correlating with early tumor stage, while low levels of miR-184 were linked
with tumor recurrence in early-stage adult-type granulosa cell tumor patients [70].
A comparative study of miRNA regulation on FOXL2 between adult-type and juvenile-
type granulosa cell tumors showed that reduction of the miR-17 family indirectly increased
FOXL2 mRNA expression [71]. Through miRNA profiling, juvenile- and adult-derived
cell-lines have been shown to be biologically distinct, but this still needs to be addressed
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in vivo. Different studies by Tu et al. showed that miR-10a promotes granulosa cell tumor
development via the PTEN-AKT/Wnt regulatory axis, while miR-126 is a tumor suppressor
of granulosa cell tumor development via the regulation of EGFL7 [72,73].
Mutations in the RNase IIIb domain of DICER1 are a common feature of nonep-
ithelial ovarian tumors. These mutations lead to impaired miRNA biogenesis and thus
disrupt miRNA levels. Mutations in both copies of DICER1 result in the so- called DICER1
syndrome, and ovarian Sertoli-Leydig tumors are highly characteristic of this syndrome.
Sertoli–Leydig tumors contain DICER1 mutations in a high proportion of cases [74]. Hence,
targeted therapies based on unique molecular pathways may be promising for better cure
rates while reducing serious side effects.
4.2. Uterine Cancer
Uterine cancer can arise from both the endometrium and the myometrium. Uterine
sarcomas, which arise from the middle muscular layer, are rare but are often aggressive
and therefore need prompt diagnosis and treatment. Endometrial carcinoma is the most
common type of gynecological cancer in women in developed countries, and it has been
traditionally classified into two histological types. Type I tumors make-up 80–90% of
endometrial cancers and are typically characterized by a low-grade endometrioid histol-
ogy, on a background of atypical hyperplasia. These are characterized by estrogen and
progesterone receptor positivity and, in most cases, have a favorable prognosis. Type II
cancer occurs in 10–20% of endometrial cancers and is associated with typically high-grade
non-endometrioid histology (serous endometrial cancer; clear cell endometrial cancer;
uterine carcinosarcoma, UCS), arising in atrophic endometria. This is usually estrogen-
independent and has a higher risk for metastases and less favorable prognosis [75].
4.2.1. miRNAs in Uterine Sarcomas
Uterine sarcomas are aggressive mesenchymal tumors, with an incidence of 2–3%
of all uterine malignancies [76]. There is a lack of consensus on risk factors and optimal
treatment due to their rarity and diversity in their histopathology, thus generally leading
to poor outcomes. Leiomyosarcoma (LMS), undifferentiated sarcoma and endometrial
stromal sarcoma (ESS) are the predominant uterine sarcomas, with even rarer types such as
rhabdomyosarcoma (including embryonal type in the cervix), and adenosarcomas [4,77].
ESS represents the second most common category of mesenchymal uterine tumors, in
spite of accounting for less than 1% of all uterine tumors [76]. Endometrial sarcomas are
further classified into low-grade ESS and high-grade ESS. Low- and high-grade ESS have
been found to differ on a molecular level. Low-grade ESS is also a much more hormone-
responsive and indolent tumor, whereas high-grade ESS is a more aggressive tumor [76].
This category was re-introduced into the WHO classification in 2014, and it is recognized
that there is more than one molecular subtype of this tumor based on translocations [78,79].
Low-grade ESS are treated mainly by hysterectomy and bilateral salpingo-oophorectomy,
but may include adjuvant radiation, hormonal treatment or aromatase inhibitors [80].
Patients with high-grade ESS have a higher mortality due to earlier and more fre-
quent recurrences (often <1 year). Advanced or recurrent tumors must be treated aggres-
sively with a combination of chemotherapyand radiation [81]. The role of maintenance
therapy with treatments such as cabozantinib in high-grade uterine sarcoma are being
investigated [82].
LMS is the most common uterine sarcoma. It occurs in women over 40 years of age
and has a 50% 5-year survival rate when confined to the uterus. It appears that adjuvant
chemotherapy or radiotherapy does not incur any added benefit [83]. Signs and symptoms
of LMS resemble those of leiomyoma, which is more common, and hence the preoperative
distinction between the two tumors may be difficult. In postmenopausal women who
are not using hormonal replacement therapy, malignancy can be suspected by the tumor
growth, although it is rare for a leiomyosarcoma to present as a rapidly growing tumor [76].
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Treatment of leiomyosarcomas involves total abdominal hysterectomy with debulking
of the tumor in case of local metastasis. Doxorubicin, docetaxel/gemcitabine, and ifos-
famide are all possible treatment options for advanced or recurrent disease. Some tumors
may respond to hormonal treatment [76]. Targeted therapies such as trabectedin and
pazopanib have been investigated as treatment in advanced stage or metastatic leiomyosar-
coma, with some degree of efficacy in disease control [76,84]. When compared to usual
type leiomyomas, mutations in the cell cycle genes are more common in leiomyosarcoma
samples. Hence, cell cycle-related mechanisms could be attractive targets for treatment for
these rare tumors [85].
Undifferentiated sarcoma has no identifiable molecular marker and is essentially a
diagnosis of exclusion. This is an aggressive cancer, and treatment options are deduced
from experience with other high-grade soft tissue sarcomas. Clinical trials for the targeted
therapies in soft tissue sarcomas are enrolling patients with uterine sarcoma [4]. While this
enables the involvement of more patients into the clinical trials, it may hinder the specific
analysis of these subtypes [4].
There is a lack of knowledge about the roles and molecular mechanisms of miRNAs
in the physiological and pathological processes and about any correlation with progno-
sis and their potential to predict treatment outcome in patients with uterine sarcomas.
Gonzalez Dos Anjos et al. analyzed miRNA expression profiles linked with the cancer-
specific survival (CSS) of patients with uterine sarcomas [86]. In particular, in leiomyosar-
coma, an association of lower CSS was found with the downregulation of miR-10a-5p and
miR-125a-5p, and the upregulation of miR-34c-5p and miR-196a-5p. In endometrial stromal
sarcomas, the down-regulation of miR-23-3p, let-7b-5p and let-7f-5p and the upregulation
of miR-372-3p and miR-373-3p were associated with lower CSS. Higher survival rates
were linked only to miR-138-5p upregulation. Patients with tumor metastasis and relapse
had higher expression of miR-210-3p, miR-301a-3p and miR-335-5p. Finally, expression
of miR-138-5p, miR-146b-5p, and miR-218-5p was linked with higher disease-free sur-
vival in treated patients. This suggests that these miRNAs represent potential prediction
biomarkers for treatment response and prognosis in patients with such tumors.
Evaluation of the expression of 88 miRNAs known to be involved in LMS and ESS
showed downregulation of miR-1, miR-23b, let-7c and let-7f in ESS in relation to the
benign tissue. However, there were no statistically significant changes in miRNA ex-
pression levels between LMS tumors and controls [87]. In a molecular study that was
conducted to compare the miRNA profiles of LMS and ESS and to compare the miRNA
signatures of primary LMS, primary ESS and metastatic uterine LMS, 94 miRNAs were
significantly differentially expressed in LMS and ESS [88]. Out of these miRNAs, 18 were
overexpressed in LMS and 76 were overexpressed in ESS. In primary and metastatic
LMS, 49 miRNAs were differentially expressed, with 45 being overexpressed in primary
LMS and 4 overexpressed in metastases. These differing miRNA profiles in primary
and metastatic LMS might help to improve the understanding of the progression of
this malignancy. In LMS cells, five miRNAs exhibited an overexpression (miR-129-5p,
miR-141-3p, miR-148a-3p, miR-202-3p and miR-203a-3p), and eight were downregulated
(miR-1-3p, miR-21-5p, miR-27b-3p, miR-125b-1-3p, miR-140-5p, miR-152-3p, miR-485-5p
and miR-495-3p). Of these, only three miRNAs showed significant expression in LMS
(miR-1-3p, miR-202-3p and miR-7-5p). In addition, let-7 was also shown to be a potential
prognostic biomarker in LMS [89,90].
In 2014, Guled et al. analyzed miRNA profiling on a series of LMS and undifferentiated
pleomorphic sarcoma (UPS) samples, and in total, 38 and 46 miRNAs classified UPS and
LMS samples, respectively, were compared to control samples. There was differential
expression of miR-22, miR-126, miR-199a-3p, miR-199b-5p and miR-320a. In particular,
miR-320a and miR-199-5p were highly expressed in LMS and UPS, respectively [91].
Finally, Stope et al. demonstrated that miR-1 is suppressed in LMS, compared to
adjacent healthy tissue [92]. Moreover, in vitro studies suggested that miR-1 may be a
pivotal tumor suppressor and represent a promising biomarker of diagnosis in LMS therapy.
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Overall, changes in miRNA levels are potentially important in terms of genomic copy
number changes at miRNA gene loci and mRNA targets of these dysregulated miRNAs,
which can have further implications in disease mechanisms.
4.2.2. miRNAs in Uterine Carcinosarcomas
Uterine carcinosarcoma (UCS) is another rare gynecological cancer which accounts
for less than 5% of uterine cancers [93]. It is a metaplastic carcinoma that is highly lethal
with a 5-year survival rate of 33–39% [94]. Adjuvant treatment in case of metastasis largely
includes the use of paclitaxel and carboplatin. To date, there is no trial that has shown an
OS benefit from adjuvant radiotherapy or chemotherapy, even though most of these trials
included a variety of gynecological sarcomas [95–97].
UCS is a biphasic tumor consisting of both mesenchymal (sarcomatous) and epithelial
(carcinomatous) components. The mesenchymal component can resemble homologous
histologic components commonly found in the uterus, or harbor heterologous components
that are not normally native to the uterus, such as chondrosarcomatous or rhabdomyosar-
comatous differentiation, and is by definition high-grade. The epithelial component is also
high-grade and usually shows serous or endometrioid differentiation [98]. UCS shares
mutational features similar to serous uterine carcinoma more frequently than endometrioid
histologies, with extensive copy number alterations, and the majority harbor somatic TP53
mutations. However, TP53 mutation was found to be less common in “endometrioid”
tumors [99]. UCSs are believed to have a monoclonal origin where, according to the
conversion theory, carcinomatous subclones can undergo metaplastic differentiation to
transform into sarcomatous cells late in tumorigenesis [100]. This conversion theory is
backed by the fact that there is the co-expression of epithelial membrane antigens and
cytokeratins in sarcomatous and carcinomatous cells, as well as identical patterns of X
chromosome inactivation, concordance of TP53 and KRAS mutations, and similar losses
of heterozygosity between sarcomatous and carcinomatous components. Other frequent
mutations have been found in PIK3CA, FBXW7, TP53, KRAS, PPP2R1A, and PTEN, similar
to serous and endometrioid uterine carcinomas [100].
It has still not been determined how carcinomatous cells specifically undergo meta-
plastic differentiation. According to the conversion theory, it is believed that EMT allows
the sarcomatous component to be derived from the carcinomatous component. EMT is a
known process that causes cancer progression, metastasis and therapeutic resistance. The
mechanism of EMT is also reversible, where mesenchymal–epithelial transition (MET) can
decrease the progression of the tumor. Studies demonstrate that the over-expression of
miR-200 in UCS cells induces a robust MET, leading to a decreased growth and aggres-
siveness of cells both in vitro and in vivo [100,101]. This suggests that advanced miRNA
therapeutics using ectopic miR-200 expression may be a promising treatment for patients
with UCS. A strong negative association has also been shown between expression of the
miRNA-200 family and the levels of their promoter methylation. Therefore, epigenetic
regulation of these miRNAs indicates a possible a mechanism for EMT in UCS [100].
Brunetti et al. performed molecular investigations on the expression status and
mutations of the genes FHIT, HMGA1/2, MTA1 and LIN28A; the pseudogenes HMGA1P6
and HMGA1P7; and the miRNAs known to influence expression of these same genes
in ovarian carcinosarcomas and UCS [98]. Mutations in KRAS, PIK3CA, and TP53 were
identified in UCS with a frequency of 6%, 31%, and 75%, respectively. In addition, an
inverse correlation between downregulation of miRNAs such as miR16, miR26a, miR30c,
miR214, let-7a and let-7d, and overexpression of HMGA1/2, and MTA1, were observed [98].
4.3. miRNAs in Vulvar Tumors
Vulvar carcinoma is also considered rare, accounting for 5% of female genital tract
cancers, with the highest incidence in women aged 65 to 75 years. Patients with advanced
or recurrent disease have a poor outcomes and increased morbidity [64,102]. Over 85%
of cases are squamous cell carcinoma, and risk factors include human papillomavirus
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(HPV) infection, lichen sclerosus, and, especially in young women, vulvar intraepithelial
neoplasia. Other histologic types also occur, including basal cell carcinoma, Bartholin gland
carcinoma, extramammary Paget disease, sweat gland adenocarcinoma, adenocarcinoma of
intestinal type, germ cell tumors, melanoma (see below) and mesenchymal tumors [63,102].
Treatment often consists of surgical management, which is then followed by radio-
therapy with or without chemotherapy. Management of these patients is largely based on
experience from the treatment of advanced cervical cancers [4].
Targeted therapies with potential benefit in vulvar carcinoma include TKIs such
as erlotinib and cetuximab as EGFR genomic amplification and overexpression have
been associated with poor survival in these patients. Erlotinib and combination cetux-
imab with chemotherapy in patients with recurrent vulvar carcinoma showed substantial
response [103,104].
In addition, HER2 expression was also detected in extramammary Paget disease of the
vulva. Although Paget disease is believed to have a good prognosis, recurrence is frequent.
Hence, treatments targeted to HER2 may also benefit recurrent Paget disease of the vulva
with HER2 overexpression [105].
High-risk HPV infection is related to vulvar intraepithelial neoplasia, basaloid, and
warty carcinomas. In a retrospective study, p16 immunohistochemistry was positive in 166
of 550 tumors (30.2%) and p53 staining in 187 of 597 tumors (31.3%) [106]. Dysregulated
cell cycle markers including increased expression of cyclin D1, and cyclin A has also
been shown in vulvar carcinomas. These markers are related to poor clinical outcomes.
Therefore, targeted agents for these molecular pathways, including a therapeutic HPV
vaccine, are potential treatments for vulvar carcinoma [64].
Currently, there is limited information regarding the expression of miRNAs in vul-
var carcinoma. de Melo Maia et al. characterized microRNA profile in vulvar tumors,
correlating it with clinical and histopathologic data, and the occurrence of HPV infec-
tion [107]. There were 25 differentially expressed miRNAs between HPV-negative and
HPV-positive groups, and 79 differentially expressed in tumors when compared to normal
samples. Moreover, downregulation of both miR-19-b1-5p and miR-223-5p correlated with
the presence of lymph node metastasis. Furthermore, downregulation of miR-19-b1-5p
and miR-100-3p were associated with vascular invasion. In addition, overexpression of
miR-133a and miR-519b were linked with advanced FIGO stage.
Yang and Wu investigated the mechanism of action of miRNAs in vulvar squamous
cell carcinoma (VSCC) [108]. Altered expression of 157 miRNAs was detected in this
type of carcinoma, with upregulation of miR-182-5p, miR-183-5p and miR-590-5p, and
downregulation of miR-103a-3p, miR-107 and miR-603. There was a positive relationship
between lymph node metastasis and miR-590-5p expression. Finally, upregulation of
miR-590-5p may promote cellular malignant behavior via the target gene TGFβR II. In
another study, there was an increased level of expression of miRNA-4712-5p in VSCC,
promoting proliferation and invasion, by affecting PTEN and its downstream p-GSK3β,
p-AKT, and cyclin D1 signaling pathways [109]. It has also been shown that miR-3147
serves as an oncomiR in VSCC via suppression of Smad4 [110]. These findings suggest
future clinical applications related to miRNA deregulation in vulvar carcinoma.
4.4. miRNAs in Melanoma of the Female Genital Tract
Malignant melanoma, which overall accounts for around 1% of all cancers, is a malig-
nant neoplasm of the skin and mucous membranes. The mucosal malignant melanomas,
which are rarer and account for 0.03% of all cancers, may occur in various sites including
the conjunctiva, oral cavity, esophagus, anus, and even the gynecological tract [111]. In
fact, in women, 3% to 7% of all cases of mucosal malignant melanoma develop within the
genital tract, mainly in the vulva and vagina. However, primary malignant melanoma of
the uterine cervix is even rarer, with a five times lower incidence than primary vaginal
or vulva cases of malignant melanoma [112]. Radical hysterectomy with regional lym-
phadenectomy and/or concurrent chemoradiation therapies are generally recommended,
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but the prognosis is usually poor and unpredictable. This is because there has been no
absolute agreement on comprehensive treatment to date, due to its rarity and difficulty
in diagnosis.
Recently, DiVincenzo et al. investigated miRNA expression profiles in melanomas
originating from gynecological sites, such as cervix, vulva and vagina [113]. When
comparing miRNA expression in vaginal melanoma to normal adjacent vaginal mu-
cosal tissue, 25 differentially expressed miRNAs, were found. Moreover, 45 differentially
expressed miRNAs were identified between vulvar melanoma and primary cutaneous
melanoma, among which three demonstrated a decrease in expression in vulvar melanoma
(miR-200a-3p, miR-200b-3p and miR-494-3p), and 44 demonstrated an increase in expres-
sion (including miR-17-5p, miR-146a-5p, and miR19b-3p). Among these differentially
expressed miRNAs, both miR-17-5p and miR-146a-5p have been experimentally validated
as direct or indirect regulators of PD-L1 expression in melanoma [114,115]. Furthermore,
pathway analysis for differentially expressed miRNAs in vulval and vaginal melanoma has
shown significant enrichment of 30 and 35 pathways, respectively, each including TGF-β
signaling. In these cases, 57 genes in the pathway are validated targets of 13 differentially
expressed miRNAs in vaginal melanoma, and 59 genes in the pathway are validated targets
of 17 differentially expressed miRNAs in vulvar melanoma. These results indicate that
miRNAs have an important role as potential regulators of gene expression in vaginal and
vulvar melanomas, thus contributing to tumor progression.
4.5. miRNAs in Gestational Trophoblastic Disease
Gestational trophoblastic disease (GTD), which has an incidence of
2.0 per 1000 pregnancies refers to abnormal trophoblastic proliferation leading to a broad
spectrum of lesions ranging from the benign, to premalignant, hydatidiform mole, through
to gestational trophoblastic neoplasia (GTN), which encompasses the aggressive invasive
mole, choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic
tumor [78,116,117]. GTN is also referred to as persistent trophoblastic neoplasia (PTN)
because it may arise after a normal term or preterm pregnancy, a molar pregnancy, abortion,
or even an ectopic pregnancy. Although patients with GTN generally show a good response
with more than 90% cure rate following chemotherapy, around 4% of cases would succumb
to the disease [118].
The exact molecular mechanisms of the etiopathogenesis of GTD are still unclear. Hu-
man chorionic gonadotropin (HCG) is associated with excessive trophoblastic proliferation
and can act as an angiogenic factor during implantation of molar pregnancy [119]. Thus,
high HCG concentrations may increase the risk of persistent GTN. Hence, the efficacy of
antiangiogenic agents should be explored for GTN.
Although more is now known regarding placenta-associated miRNAs, there is a
lack of information regarding their role in the pathogenesis and progression of GTD. In
complete hydatidiform mole, there is dysregulation of miR-517a, miR-517b, miR-518b, and
miR-519a [120]. In cells derived from choriocarcinoma, miR-371a-5p and miR-518a-3p
regulated different pathways related to tumorigenesis and metastasis [121]. These results
may offer new clues to the proliferation and metastasis of GTD and may even provide
possible diagnostic biomarkers for GTN.
It has been shown that miR-181b-5p, miR-181d-5p and miR-371a-5p are the most
significantly altered miRNAs which are associated with progression to GTN [122]. Finally,
other studies showed that miR-21 is involved in proliferation, migration, and invasion of
choriocarcinoma cells, while miR-34, miR-196b and miR-199b may be tumor suppressors
in choriocarcinoma [123–126].
5. Circulating miRNAs as Potential Biomarkers
To date, miRNAs have been detected in body fluids such as plasma/serum, saliva,
cerebrospinal fluid, breast milk, pleural effusion, ascites, urine and vaginal discharge. This
presents an opportunity as a non-invasive liquid biopsy approach for the diagnosis of
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a wide range of cancers [127–129]. Thus, miRNAs present in these fluids may serve as
biomarkers offering easy and rapid non-invasive tests [130–133]. Additionally, extracellular
miRNAs can be delivered to target cells by binding to proteins, such as argonautes [134] or
via vesicles, such as exosomes, acting as endocrine, autocrine, and/or paracrine regulators
and modulators of cellular activities [135]. This suggests that miRNAs may have hormone-
like activities. Therefore, extracellular and circulating miRNAs can serve as biomarkers for
diseases, as well as a means of intercellular communication.
Zhang et al. demonstrated through high-throughput sequencing, that plasma ex-
osomes from women with ovarian cancer and healthy controls differently expressed
miRNAs [136]: 31 were found to be downregulated and 34 upregulated. miR-99b-5p,
miR-122-5p and miR-185-5p were significantly decreased, and miR-93-5p, miR-106a-5p and
let-7d-5p expression levels were significantly increased, in patients with ovarian cancer
compared with healthy women. Another study where circulating miRNA profiling was
carried out in plasma samples of ovarian cancer patients, a variety of differentially ex-
pressed miRNAs were identified as possible biomarkers for the diagnosis, e.g., miR-19b-3p,
miR-26b-5p, miR-125a-3p, miR-144-3p, miR-337-5p and miR-500a-5p [137]. However, to
date, there are few studies on potential miRNAs as biomarkers for the diagnosis and
prognosis of patients with RGCs (Table 2).






























In 2014, Chao et al. analyzed the sera of patients with clear cell carcinoma and found
that, in a set of 11 pairs of pre- and postoperative sera, the levels of four miRNAs (miR-130a,
miR-138, miR-187 and miR-202) were higher in the sera of preoperative patients [138]. In
addition, miR-130a remained consistent during the different time points in seven of the
10 patients during clinical follow-up. This suggests that miR-130a may be a useful serum
biomarker for detecting the recurrence of OCCC.
Murray et al. showed that there were elevated levels of all eight main members of the
miR-371∼373 and miR-302 clusters in the serum of a four-year-old child at diagnosis of yolk
sac tumor [139]. Moreover, miRNA levels returned to normal during the clinical follow-up,
with kinetics similar to a conventional marker α-fetoprotein. This study indicates that
miR-371∼373 and miR-302 clusters could be promising candidate biomarkers for disease
monitoring in malignant germ-cell tumors. A serum panel of choriocarcinoma-specific
“chromosome-19-microRNA-cluster” (C19MC) microRNAs have been identified and were
highly elevated at diagnosis but dropped rapidly upon starting treatment and normalized
prior to the start of the second full chemotherapy course [140]. At diagnosis, the same
authors also reconfirmed serum elevation of the previously identified marker of malignant
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germ-cell tumors, miR-371a-3p. Thus, these circulating microRNA markers seem to reflect
choriocarcinoma disease activity more accurately than serum hCG, thus having potential
in assisting clinical decision-making.
Circulating miRNAs were also investigated as potential biomarkers for leiomyosar-
coma (LMS) [141]. The optimal model consisted of two miRNAs (miR-191-5p and miR-1246),
with an area under the receiver operating characteristic curve for identifying LMS of
0.97 (95% confidence interval, 0.91–1.00). Seven serum miRNAs, namely miR-191-5p,
miR-451a, miR-1246, miR-4430, miR-4485-5p, miR-4635 and miR-6511b-5p, were identified
as a promising diagnostic model for LMS.
Finally, there is a significant decrease in plasma levels of miR-520b, -520c-3p and
-520f in patients with complete hydatiform mole after evacuation [142]. Interestingly,
in GTN patients, these three miRNAs tended to have a similar variation to serum hCG
concentration [143].
The combination of multiple circulating miRNAs may be promising biomarkers for
the diagnosis of gynecological cancers, including RGCs. However, inconsistent results of
different study designs hamper the applicability of these findings as robust biomarkers.
Therefore, further studies are required to validate these results.
In addition, 3′-UTR length isoform diversity is another issue in miRNA based gene
regulation in cancers. 3′-UTR cis-elements recognized by miRNAs and/or RNA-binding
proteins have a significant impact on the fate of mRNAs [144]. Alternative polyadenylation
and/or splicing alters the 3′-UTR lengths in normal tissues and in cancer cells [145–149].
These 3′UTR isoforms are generally tissue and cancer-type-specific and hence have been
suggested as potential biomarkers with prognostic potential [150–152]. Functionally rele-
vant 3′UTR shortening or lengthening events may alter the miRNA binding landscape in
cancer transcriptomes. Isoforms with different 3′UTR lengths are likely to be targeted differ-
ently by miRNAs, adding an extra level of complexity with implications at the translation
step. Currently, there are few studies on ovarian cancers; hence our understanding of the
3′UTR diversity in gynecological cancers is very limited [152,153]. As transcriptome-level
complexities are beginning to be investigated in gynecological cancers, a more comprehen-
sive view of miRNA-based regulation is likely in the near future.
6. A Brief Overview on miRNAs and Their Regulated Targets in RGCs
The little evidence to date for miRNA functional targets is largely derived from
reporter assays in combination with the cellular effects of modulation of miRNA expression
in cell culture. We will proceed with describing miRNAs that may represent novel potential
therapeutic targets for RGCs.
6.1. Up-/Down-Regulated miRNAs and Their Roles in RGCs
Several miRNAs that are overexpressed in RGCs have been shown to have oncogenic
roles in vitro, as well as defined molecular targets that they regulate (Table 3). miR-9 [55],
miR-10a [73], miR-21 [126], miR-590-5p [108], miR-3147 [110] and miR-4712 [109] have been
described as “oncomiRs” across multiple mammalian cell types, which is consistent with
their role in RGCs. In addition, underexpressed miRNAs in RGCs such as miR-34 [124],
miR-126 [72] and miR-196b [125] act as tumor suppressors.
6.1.1. miR-9 Induces EMT by CDH1 Targeting
Depending on the tissue type, miR-9 can act as a tumor suppressor or as an oncomiR.
Similar to previous studies describing many other types of cancer [154], Yanaihara et al. [55]
observed that there is an increased miR-9 expression in OCCC. In addition, luciferase-based
assays have demonstrated direct binding between miR-9 and E-cadherin, which is a tumor
suppressor protein encoded by the CDH1 gene. The loss of its expression in association with
EMT occurs frequently during tumor metastasis [155]. Moreover, miR-9 knockdown also
limits invasion and migration while upregulating E-cadherin expression. This suggests that
aberrant miR-9 expression might play an important role in EMT activation in OCCC cells
Int. J. Mol. Sci. 2021, 22, 3822 16 of 26
via direct binding to and downregulation of E-cadherin. Therefore, miR-9 upregulation
may be involved in OCCC pathogenesis by inducing EMT through E-cadherin modulation.
Accordingly, miR-9 may be a promising therapeutic target strategy for OCCC [55].
Table 3. Validated mRNA targets and affected pathways of miRNAs relevant in RGCs.
miRNA Up- orDown-Regulated Validated Targets
Pathway/Process
Affected Cell Line References
miR-9 Upregulated CDH1 EMT OCCC [55]
miR-10a Upregulated PTEN Akt and Wnt pathways Cancerousgranulosa [73]
miR-21 Upregulated PDCD4 Akt pathway Choriocarcinoma [126]
miR-590-5p Upregulated TGFβRII TGFβ pathway VSCC [108]
miR-3147 Upregulated SMAD4 TGFβ pathway VSCC [110]
miR-4712-5p Upregulated PTEN AKT, GSK3β and cyclinD1 signaling pathways VSCC [109]
miR-34a Downregulated DLL1 Notch pathway Choriocarcinoma [124]
miR-126 Downregulated EGFL7 PI3K/AKT pathway Cancerousgranulosa [72]
miR-196b Downregulated MAP3K1 Cell migrationand invasion Choriocarcinoma [125]
6.1.2. miR-10a Promotes Tumorigenesis by Regulating PTEN, Akt and Wnt Pathways
In patients with acute myeloid leukemia, miR-10a acts as an oncomiR via its repres-
sion of the p53/Rb network [156]. The microRNA-10 family could disturb the normal
development of granulosa cells during follicle formation, and there is a strong miR-10a
signal in tissues from malignant granulosa cell tumor patients [157]. Moreover, in vitro,
forced expression of miR-10a promotes cell proliferation, invasion, migration, ovarian hor-
mone production, and repressed anticancer drug-induced apoptosis. The oncogenic role of
miR-10a was also validated in vivo. Interestingly, PTEN, a well-known tumor suppressor,
was identified as a direct functional target of miR-10a, and AKT/Wnt as an associated
oncogenic pathway of miR-10a in cancerous granulosa cells. These results demonstrate
that miR-10a can promote granulosa cell tumor development via regulating PTEN, Akt,
and Wnt pathways [73].
6.1.3. miR-21 Targeted PDCD4 and PTEN Genes
miR-21 is one of the most commonly upregulated miRNAs in different types of
malignant tumors [158]. Moreover, miR-21 is implicated in various processes involved
in carcinogenesis such as proliferation, invasion, and metastasis. Meanwhile, miR-21
also participates in the regulation of multiple signaling pathways such as Nanog/STAT3,
PI3K/Akt and PDGF pathways [158]. The regulatory function of miR-21 depends on its
target genes such as PTEN and PDCD4 (programmed cell death 4), which are both tumor
suppressors [158].
Wang et al. [126] demonstrated the miR-21 could promote proliferation, invasion
and migration of choriocarcinoma cells. Furthermore, miR-21 can activate the Akt path-
way, negatively regulates PDCD4 and PTEN and targets PDCD4 in choriocarcinoma cells.
This suggests that miR-21 is responsible for the aggressive phenotype of gestational tro-
phoblastic disease and may have a potential diagnostic and therapeutic role to play in
this condition.
6.1.4. miR-590-5p Promotes Cellular Malignant Behaviors via the Target Gene TGFβRII
It has been reported that miR-590-5p promotes proliferation and invasion in human
hepatocellular carcinoma cells via the direct targeting of TGF-βRII, which in turn plays
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an important role in cell growth and cancer development [159]. Yang and Wu found a
positive relationship between miR-590-5p expression and lymph node metastasis [108].
Furthermore, they showed that miR-590-5p plays an oncogenic role in VSCC by promoting
cell proliferation and migration through the manipulation of TGFβRII expression. This
suggests that miR-590-5p may be a critical therapeutic target in VSCC.
6.1.5. miR-3147 Regulates SMAD4
It has been shown that there is upregulation of miR-3147 in cervical squamous cancer
and melanoma [160,161]. In VSCC, the expression of miR-3147 is markedly upregulated and
the increased expression of miR-3147 is positively associated with the depth of invasion (4).
In addition, miR-3147 regulates SMAD4 by directly binding to its 3′ untranslated region.
These results indicate that miR-3147 may have an oncogenic role in VSCC by targeting
SMAD4, and miR-3147 may represent a novel potential therapeutic target for VSCC [110].
6.1.6. miR-4712-5p Regulates PTEN and Affects Its Downstream p-AKT, p-GSK3β and
Cyclin D1 Signaling Pathways
Yang et al. [109] investigated the role of miR-4712-5p and its regulatory mechanism
in VSCC, and found increased levels of miR-4712-5p both in VSCC tissues and the A431
cell line. Moreover, miR-4712-5p overexpression promotes proliferation and invasion
of VSCC cells. Luciferase-based assays have also demonstrated direct binding between
miR-4712-5p and PTEN. In addition, miR-4712-5p overexpression increased phospho-AKT
(p-AKT) and cyclin D1 expression, whilst there was a decrease in PTEN and phospho-
GSK3β (p-GSK3β). Therefore, miR-4712-5p can reduce the expression of PTEN, further
affecting its downstream p-AKT, p-GSK3β and cyclin D1 signaling pathways, promoting
the proliferation and invasion of VSCC.
6.1.7. miR-126 Regulates EGFL7
Epidermal growth factor-like domain-containing protein 7 (EGFL7) has been shown
to be a critical oncogene in various types of cancer [162–165]. Notably, EGFL7 is highly
expressed in patients with EOC, and its expression has been correlated with a poor progno-
sis [166]. In addition, EGFL7 also serves as a potential predictive marker of chemotherapy
for cervical cancer [167].
Methylation-associated silencing of miR-126 and its host gene EGFL7 has been demon-
strated in pleural mesothelioma [168], suggesting an association between EGFL7 and
miR-126. Due to the similarities between granulosa cell tumors and those of mesothelial
lineage, Tu et al. [72] showed that miR-126 constrains the tumorigenesis of granulosa cell tu-
mors via directly targeting EGFL7 and suppressing the phosphatidylinositol 3-kinase/ATK
(PI3K/AKT) pathway. This suggests that miR-126 may be utilized as a prognostic marker
or a therapeutic target for granulosa cell tumor treatment.
6.1.8. miR-34a and miR-196b Are Tumor Suppressors in Choriocarcinoma
These miRNAs include miR-34a and miR-196b, which have been demonstrated to
have tumor-suppressor activity in human choriocarcinoma cells [124,125]. The members
of the miR-34 family share high sequence homology [169]. Among these, miR-34a is one
of the best-known miRNA tumor suppressors and is directly activated by p53 [170,171].
Pang et al. [124] demonstrated that miR-34a suppresses cell proliferation and invasion
in choriocarcinoma cells through regulation of the Notch ligand Delta-like one (DLL1).
Thus, it is possible that, in the future, miR-34a can be used as a therapeutic target for
treating choriocarcinoma.
miR-196b has been shown to function as a tumor suppressor in many different cancer
types [172–174]. A study conducted by Guo et al. demonstrated that miR-196b suppressed
proliferation, migration and invasion of human choriocarcinoma cells by inhibiting its
transcriptional target MAP3K1. miR-196b and MAP3K1 may be considered potential targets
for the clinical treatment of hydatidiform mole and possibly human choriocarcinoma [125].
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7. Conclusions and Future Directions
In summary, multiple lines of evidence suggest that miRNAs are dysregulated in
gynecological cancers. The dysregulation patterns, which need to be further confirmed in
larger cohorts, could prove to be useful in much-needed applications for diagnosis and
prognosis, as well as for therapy prediction. Based on these available and emerging data,
miRNAs could have impact in future therapeutic strategies for carcinomas of cervical,
endometrial, vaginal, vulval and ovarian origin.
To date, despite improvements in understanding the mechanisms and efficiency of
miRNA in therapeutics, there are still particular obstacles to be overcome in order to achieve
maximum efficiency. These challenges include: targeted delivery, specificity, stability,
immune activation and toxicity in vivo. Once these issues are solved, miRNA therapy will
have a major role to play in personalized medicine for various cancers, including RGCs.
GYNOCARE (a European Network for Gynaecological Rare Cancer research: from
Concept to Cure) aims to make connections between research (e.g., international, basic, and
clinical trials) on RGCs, and the pharmaceutical sector (e.g., focused on innovative, targeted
therapies). To bridge the gap between the unmet needs of women afflicted by RGCs and
the recent medical and technological advances, both clinicians and their patients need
to have good access to current information on possible participation in clinical trials, as
well as relevant education and support. For instance, providing a centralized website and
medical/coordination assistance may serve as simple steps to accomplish these goals in
the clinical setting (e.g., recruitment to research trials, or reinforced adherence to diagnostic
and therapeutic management) [5].
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BEP bleomycin, etoposide, and cisplatin
CSC Cancer Stem Cell
EMT epithelial–mesenchymal transition
ESS endometrial stromal sarcoma
GTD gestational trophoblastic disease
GTN gestational trophoblastic neoplasia
hCG human chorionic gonadotropin
HGSC high-grade serous ovarian carcinoma
HPV human papillomavirus
LMS leiomyosarcoma
mEOC mucinous ovarian cancer
miRNA/miR micro-RNA
OCCC ovarian clear cell cancer
PTEN phosphatase and tensin homolog deleted on chromosome ten
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RGC rare gynecological cancer
RISC RNA-induced silencing complex
TIP paclitaxel, ifosfamide, and cisplatin
TKIs tyrosine kinase inhibitors
TRBP transactivation response RNA binding protein
TsmiRs tumor suppressors miRs
UCS uterine carcinosarcoma
UPS undifferentiated pleomorphic sarcoma
VSCC vulvar squamous cell carcinoma
3′-UTR 3′ untranslated region
References
1. Srivastava, S.K.; Ahmad, A.; Zubair, H.; Miree, O.; Singh, S.; Rocconi, R.P.; Scalici, J.; Singh, A.P. MicroRNAs in gynecological
cancers: Small molecules with big implications. Cancer Lett. 2017, 407, 123–138. [CrossRef]
2. Maheshwari, A.; Kumar, N.; Mahantshetty, U. Gynecological cancers: A summary of published Indian data. South Asian J. Cancer
2016, 5, 112–120. [CrossRef]
3. Esserman, L.J.; Thompson, I.M.; Reid, B.; Nelson, P.; Ransohoff, D.F.; Welch, H.G.; Hwang, S.; Berry, D.A.; Kinzler, K.W.;
Black, W.C.; et al. Addressing overdiagnosis and overtreatment in cancer: A prescription for change. Lancet Oncol. 2014, 15,
e234–e242. [CrossRef]
4. Mandilaras, V.; Karakasis, K.; Clarke, B.; Amit Oza, A.; Lheureux, S. Rare tumors in gynaecological cancers and the lack of
therapeutic options and clinical trials. Expert Opin. Orphan Drugs 2017, 5, 71–83. [CrossRef]
5. Di Fiore, R.; Suleiman, S.; Ellul, B.; O’Toole, S.A.; Savona-Ventura, C.; Felix, A.; Napolioni, V.; Conlon, N.T.; Kahramanoglu,
I.; Azzopardi, M.J.; et al. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic
Tumors-Current Challenges and Future Directions. Cancers 2021, 13, 493. [CrossRef] [PubMed]
6. Ray-Coquard, I.; Trama, A.; Seckl, M.J.; Fotopoulou, C.; Pautier, P.; Pignata, S.; Kristensen, G.; Mangili, G.; Falconer, H.; Massuger,
L.; et al. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. Eur. J. Surg. Oncol. 2017, 45,
67–74. [CrossRef] [PubMed]
7. Cancer Research UK. Available online: https://www.cancerresearchuk.org (accessed on 20 February 2021).
8. Rare Cancers Europe. Available online: https://www.rarecancerseurope.org (accessed on 17 February 2021).
9. Jonas, S.; Izaurralde, E. Towards a molecular understanding of microRNA mediated gene silencing. Nat. Rev. Genet. 2015, 16,
421–433. [CrossRef] [PubMed]
10. O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation.
Front. Endocrinol. 2018, 9, 402. [CrossRef]
11. Kozomara, A.; Birgaoanu, M.; Griffiths-Jones, S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019, 47,
D155–D162. [CrossRef]
12. Zhong, X.; Coukos, G.; Zhang, L. miRNAs in human cancer. Methods Mol. Biol. 2012, 822, 295–306.
13. Rajagopal, T.; Talluri, S.; Venkatabalasubramanian, S.; Dunna, N.R. Multifaceted roles of long non-coding RNAs in triple-negative
breast cancer: Biology and clinical applications. Biochem. Soc. Trans. 2020, 48, 2791–2810. [CrossRef] [PubMed]
14. Tabatabaeian, H.; Peiling Yang, S.; Tay, Y. Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis. Cancers
2020, 12, 3264. [CrossRef]
15. Lu, X.; Zhang, Y.; Xie, G.; Ding, Y.; Cong, H.; Xuan, S. Exosomal non coding RNAs: Novel biomarkers with emerging clinical
applications in gastric cancer (Review). Mol. Med. Rep. 2020, 22, 4091–4100. [CrossRef]
16. Iorio, M.V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C.G.; Alder, H.; et al. MicroRNA
signatures in human ovarian cancer. Cancer Res. 2007, 67, 8699–8707. [CrossRef] [PubMed]
17. Miyoshi, K.; Miyoshi, T.; Siomi, H. Many ways to generate microRNA-like small RNAs: Non-canonical pathways for microRNA
production. Mol. Genet. Genom. 2010, 284, 95–103. [CrossRef] [PubMed]
18. Kim, V.N. MicroRNA biogenesis: Coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 2005, 6, 376–385. [CrossRef]
19. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanisms and function. Cell 2004, 116, 281–297. [CrossRef]
20. Abdelfattah, A.M.; Park, C.; Choi, M.Y. Update on non-canonical microRNAs. Biomol. Concepts 2014, 5, 275–287.
[CrossRef] [PubMed]
21. Han, J.; Lee, Y.; Yeom, K.H.; Nam, J.W.; Heo, I.; Rhee, J.K.; Sohn, S.Y.; Cho, Y.; Zhang, B.T.; Kim, V.N. Molecular Basis for the
Recognition of Primary microRNAs by the Drosha-DGCR8 Complex. Cell 2006, 125, 887–901. [CrossRef]
22. Valinezhad Orang, A.; Safaralizadeh, R.; Kazemzadeh-Bavili, M. Mechanisms of miRNA-Mediated Gene Regulation from
Common Downregulation to mRNA-Specific Upregulation. Int. J. Genom. 2014, 2014, 970607. [CrossRef]
23. Yuan, X.; Berg, N.; Lee, J.W.; Le, T.T.; Neudecker, V.; Jing, N.; Eltzschig, H. MicroRNA miR-223 as regulator of innate immunity.
J. Leukoc. Biol. 2018, 104, 515–524. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 3822 20 of 26
24. Zhang, Y.; Fan, M.; Zhang, X.; Huang, F.; Wu, K.; Zhang, J.; Liu, J.; Huang, Z.; Luo, H.; Tao, L.; et al. Cellular microRNAs
up-regulate transcription via interaction with promoter TATA-box motifs. RNA 2014, 20, 1878–1889. [CrossRef]
25. Daugaard, I.; Hansen, T.B. Biogenesis and Function of Ago- Associated RNAs. Trends Genet. 2017, 33, 208–219. [CrossRef] [PubMed]
26. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; et al. Frequent
deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl.
Acad. Sci. USA 2002, 99, 15524–15529. [CrossRef]
27. Acunzo, M.; Romano, G.; Wernicke, D.; Croce, C.M. MicroRNA and cancer–a brief overview. Adv. Biol. Regul. 2015, 57, 1–9.
[CrossRef] [PubMed]
28. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.;
Ferrando, A.A.; et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435, 834–838. [CrossRef] [PubMed]
29. Shimono, Y.; Zabala, M.; Cho, R.W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn, M.; Liu, H.; Panula, S.P.; Chiao, E.; et al. Downregulation
of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138, 592–603. [CrossRef]
30. Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857–866. [CrossRef]
31. Zhang, B.; Pan, X.; Cobb, G.P.; Anderson, T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302,
1–12. [CrossRef]
32. Bhardwaj, A.; Singh, S.; Singh, A.P. MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol. Cell Pharmacol.
2010, 2, 213–219.
33. Tsuda, N.; Ishiyama, S.; Li, Y.; Ioannides, C.G.; Abbruzzese, J.L.; Chang, D.Z. Synthetic microRNA designed to target glioma-
associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. Clin. Cancer Res.
2006, 12, 6557–6564. [CrossRef] [PubMed]
34. Lima, J.F.; Cerqueira, L.; Figueiredo, C.; Oliveira, C.; Azevedo, N.F. Anti-miRNA oligonucleotides: A comprehensive guide for
design. RNA Biol. 2018, 15, 338–352. [CrossRef] [PubMed]
35. Wen, D.; Danquah, M.; Chaudhary, A.K.; Mahato, R.I. Small molecules targeting microRNA for cancer therapy: Promises and
obstacles. J. Control. Release 2015, 219, 237–247. [CrossRef]
36. Gambari, R.; Brognara, E.; Spandidos, D.A.; Fabbri, E. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs:
New trends in the development of miRNA therapeutic strategies in oncology (Review). Int. J. Oncol. 2016, 49, 5–32. [CrossRef]
37. Mognato, M.; Celotti, L. MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy. Mini Rev.
Med. Chem. 2015, 15, 1052–1062. [CrossRef] [PubMed]
38. Segal, M.; Slack, F.J. Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opin. Drug Discov. 2020, 15, 987–992.
[CrossRef] [PubMed]
39. Yanai, H. Pathology of Epithelial Ovarian Tumors. In Frontiers in Ovarian Cancer Science; Katabuchi, H., Ed.; Springer: Singapore,
2017; pp. 83–113.
40. Fukunaga, M. Pathology of Non-epithelial Ovarian Tumors. In Frontiers in Ovarian Cancer Science; Katabuchi, H., Ed.; Springer:
Singapore, 2017; pp. 115–141.
41. Kurman, R.J.; Shih, I. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm.
Hum. Pathol. 2011, 42, 918–931. [CrossRef] [PubMed]
42. Fung-Kee-Fung, M.; Oliver, T.; Elit, L.; Oza, A.; Hirte, H.W.; Bryson, P. Optimal chemotherapy treatment for women with recurrent
ovarian cancer. Curr. Oncol. 2007, 14, 195–208. [CrossRef] [PubMed]
43. Zorn, K.K.; Bonome, T.; Gangi, L.; Chandramouli, G.V.; Awtrey, C.S.; Gardner, G.J.; Barrett, J.C.; Boyd, J.; Birrer, M.J.
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer
Res. 2005, 11, 6422–6430. [CrossRef]
44. Yoshida, S.; Furukawa, N.; Haruta, S.; Tanase, Y.; Kanayama, S.; Noguchi, T.; Sakata, M.; Yamada, Y.; Oi, H.; Kobayashi, H.
Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives. Cancer Treat. Rev. 2009, 35,
608–615. [CrossRef]
45. Shibuya, Y.; Tokunaga, H.; Saito, S.; Shimokawa, K.; Katsuoka, F.; Bin, L.; Kojima, K.; Nagasaki, M.; Yamamoto, M.;
Yaegashi, N.; et al. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
Genes Chromosomes Cancer 2018, 57, 51–60. [CrossRef]
46. Bitler, B.G.; Aird, K.M.; Garipov, A.; Li, H.; Amatangelo, M.; Kossenkov, A.V.; Schultz, D.C.; Liu, Q.; Shih, I.; Conejo-Garcia, J.R.;
et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 2015, 21, 231–238.
[CrossRef] [PubMed]
47. Miller, R.E.; Brough, R.; Bajrami, I.; Williamson, C.T.; McDade, S.; Campbell, J.; Kigozi, A.; Rafiq, R.; Pemberton, H.;
Natrajan, R.; et al. Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib. Mol. Cancer Ther. 2016,
15, 1472–8144. [CrossRef]
48. Bitler, B.G.; Wu, S.; Park, P.H.; Hai, Y.; Aird, K.M.; Wang, Y.; Zhai, Y.; Kossenkov, A.V.; Vara-Ailor, A.; Rauscher, F.J., III; et al.
ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat. Cell Biol. 2017, 19, 962–973. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 3822 21 of 26
49. Berns, K.; Caumanns, J.J.; Hijmans, E.M.; Gennissen, A.M.C.; Severson, T.M.; Evers, B.; Wisman, G.B.A.; Jan Meersma, G.; Lieftink,
C.; Beijersbergen, R.L.; et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene 2018, 37,
4611–4625. [CrossRef] [PubMed]
50. Fujimura, M.; Hidaka, T.; Saito, S. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth
and invasion of ovarian clear cell adenocarcinoma cells. Clin. Cancer Res. 2002, 8, 2448–2454. [PubMed]
51. Mabuchi, S.; Kawase, C.; Altomare, D.A.; Morishige, K.; Sawada, K.; Hayashi, M.; Tsujimoto, M.; Yamoto, M.; Klein-Szanto, A.J.;
Schilder, R.J.; et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma
of the ovary. Clin. Cancer Res. 2009, 15, 5404–5413. [CrossRef]
52. Anglesio, M.S.; Kommoss, S.; Tolcher, M.C.; Clarke, B.; Galletta, L.; Porter, H.; Damaraju, S.; Fereday, S.; Winterhoff, B.J.; Kalloger,
S.E.; et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting
in 19% of carcinomas. J. Pathol. 2013, 229, 111–120. [CrossRef] [PubMed]
53. Vilming Elgaaen, B.; Olstad, O.K.; Haug, K.B.F.; Brusletto, B.; Sandvik, L.; Staff, A.C.; Gautvik, K.M.; Davidson, B. Global miRNA
expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p
as a prognostic marker. BMC Cancer 2014, 14, 80. [CrossRef]
54. Wu, X.; Ruan, Y.; Jiang, H.; Xu, C. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by
downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma. Int. J. Biochem. Cell Biol. 2017, 85, 66–74. [CrossRef]
55. Yanaihara, N.; Noguchi, Y.; Saito, M.; Takenaka, M.; Takakura, S.; Yamada, K.; Okamoto, A. MicroRNA Gene Expression Signature
Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma. PLoS ONE 2016, 11, e0162584. [CrossRef] [PubMed]
56. Jang, S.G.; Yoo, C.W.; Park, S.Y.; Kang, S.; Kim, H.K. Low expression of miR-449 in gynecologic clear cell carcinoma. Int. J. Gynecol.
Cancer 2014, 24, 1558–1563. [CrossRef] [PubMed]
57. Dai, F.; Zhang, Y.; Chen, Y. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian
carcinoma. Hum. Pathol. 2014, 45, 1285–1293. [CrossRef] [PubMed]
58. Agostini, A.; Brunetti, M.; Davidson, B.; Tropé, C.G.; Eriksson, A.G.Z.; Heim, S.; Panagopoulos, I.; Micci, F. The microRNA
miR-192/215 family is upregulated in mucinous ovarian carcinomas. Sci. Rep. 2018, 23, 11069. [CrossRef] [PubMed]
59. Bower, M.; Fife, K.; Holden, L.; Paradinas, F.J.; Rustin, G.J.; Newlands, E.S. Chemotherapy for ovarian germ cell tumours. Eur. J.
Cancer 1996, 32A, 593–597. [CrossRef]
60. Simone, C.G.; Markham, M.J.; Dizon, D.S. Chemotherapy in ovarian germ cell tumors: A systematic review. Gynecol. Oncol. 2016,
141, 602–607. [CrossRef]
61. Goulvent, T.; Ray-Coquard, I.; Borel, S.; Haddad, V.; Devouassoux-Shisheboran, M.; Vacher-Lavenu, M.C.; Pujade-Laurraine, E.;
Savina, A.; Maillet, D.; Gillet, G.; et al. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: A GINECO Group
study. Histopathology 2016, 68, 279–285. [CrossRef]
62. Ray-Coquard, I.; Weber, B.; Lotz, J.P.; Tournigand, C.; Provencal, J.; Mayeur, D.; Treilleux, I.; Paraiso, D.; Duvillard, P.; Pujade-
Lauraine, E.; et al. Management of rare ovarian cancers: The experience of the French website “Observatory for rare malig-
nant tumours of the ovaries” by the GINECO group: Interim analysis of the first 100 patients. Gynecol. Oncol. 2010, 119,
53–59. [CrossRef]
63. WHO Classification of Tumors Editoral Board. Female Genital Tumors. In WHO Classification of Tumors Series, 5th ed.; IARC:
Lyon, France, 2020; Volume 4, Available online: https://publications.iarc.fr/592 (accessed on 20 December 2020).
64. Manchana, T.; Ittiwut, C.; Mutirangura, A.; Kavanagh, J.J. Targeted therapies for rare gynaecological cancers. Lancet Oncol. 2010,
11, 685–693. [CrossRef]
65. Kommoss, S.; Anglesio, M.S.; Mackenzie, R.; Yang, W.; Senz, J.; Ho, J.; Bell, L.; Lee, S.; Lorette, J.; Huntsman, D.G.; et al.
FOXL2 molecular testing in ovarian neoplasms: Diagnostic approach and procedural guidelines. Modern Pathol. 2013, 26,
860–867. [CrossRef]
66. Jamieson, S.; Fuller, P.J. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr. Rev. 2012, 33, 109–144. [CrossRef]
67. Weis-Banke, S.E.; Lerdrup, M.; Kleine-Kohlbrecher, D.; Mohammad, F.; Sidoli, S.; Jensen, O.N.; Yanase, T.; Nakamura, T.; Iwase,
A.; Stylianou, A.; et al. Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors. Cancer Res.
2020, 80, 3466–3479. [CrossRef]
68. Chang, R.K.; Li, X.; Mu, N.; Hrydziuszko, O.; Garcia-Majano, B.; Larsson, C.; Lui, W.O. MicroRNA expression profiles in
non-epithelial ovarian tumors. Int. J. Oncol. 2018, 52, 55–66. [CrossRef] [PubMed]
69. Poynter, J.N.; Bestrashniy, J.R.; Silverstein, K.A.; Hooten, A.J.; Lees, C.; Ross, J.A.; Tolar, J. Cross platform analysis of methylation,
miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology. BMC
Cancer 2015, 15, 769. [CrossRef]
70. Cheng, W.T.; Rosario, R.; Muthukaruppan, A.; Wilson, M.K.; Payne, K.; Fong, P.C.; Shelling, A.N.; Blenkiron, C. MicroRNA
profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markers. Clin. Epigenetics 2017, 9, 72.
[CrossRef] [PubMed]
71. Rosario, R.; Blenkiron, C.; Shelling, A.N. Comparative study of microRNA regulation on FOXL2 between adult-type and
juvenile-type granulosa cell tumours in vitro. Gynecol. Oncol. 2013, 129, 209–215. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 3822 22 of 26
72. Tu, J.; Cheung, H.H.; Lu, G.; Chan, C.L.K.; Chen, Z.; Chan, W.Y. microRNA-126 Is a Tumor Suppressor of Granulosa Cell Tumor
Mediated by Its Host Gene EGFL7. Front. Oncol. 2019, 9, 486. [CrossRef]
73. Tu, J.; Cheung, H.H.; Lu, G.; Chen, Z.; Chan, W.Y. MicroRNA-10a promotes granulosa cells tumor development via PTEN-
AKT/Wnt regulatory axis. Cell Death Dis. 2018, 9, 1076. [CrossRef] [PubMed]
74. De Kock, L.; Terzic, T.; McCluggage, W.G.; Stewart, C.J.R.; Shaw, P.; Foulkes, W.D.; Clarke, B.A. DICER1 Mutations Are
Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. Am. J. Surg. Pathol. 2017, 41,
1178–1187. [CrossRef]
75. Huvila, J.; Pors, J.; Thompson, E.F.; Gilks, C.B. Endometrial carcinoma: Molecular subtypes, precursors and the role of pathology
in early diagnosis. J. Pathol. 2021, 253, 355–365. [CrossRef]
76. Mbatani, N.; Olawaiye, A.; Prat, J. Uterine sarcomas. Int. J. Gynecol. Obstet. 2018, 143, 51–58. [CrossRef]
77. Ferrandina, G.; Aristei, C.; Biondetti, P.R.; Cananzi, F.C.M.; Casali, P.; Ciccarone, F.; Colombo, N.; Comandone, A.; Corvo’, R.;
De Iaco, P.; et al. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa’ italiana di
Ginecologia E Ostetricia). Eur. J. Cancer 2020, 139, 149–168. [CrossRef] [PubMed]
78. Kurman, R.J.; Carcangiu, M.L.; Herrington, C.S.; Young, R.H. WHO Classification of Tumors of Female Reproductive Organs; IARC:
Lyon, France, 2014.
79. Micci, F.; Heim, S.; Panagopoulos, I. Molecular pathogenesis and prognostication of “low-grade” and “high-grade” endometrial
stromal sarcoma. Genes Chromosomes Cancer 2020, 60, 160–167. [CrossRef] [PubMed]
80. Spano, J.P.; Soria, J.C.; Kambouchner, M.; Piperno-Neuman, S.; Morin, F.; Morere, J.F.; Martin, A.; Breau, J.L. Long-term survival
of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med. Oncol. 2003, 20, 87–93. [CrossRef]
81. Tanner, E.J.; Garg, K.; Leitao, M.M., Jr.; Soslow, R.A.; Hensley, M.L. High grade undifferentiated uterine sarcoma:
Surgery, treatment, and survival outcomes. Gynecol. Oncol. 2012, 127, 27–31. [CrossRef]
82. Ray-Coquard, I.; Hatcher, H.; Bompas, E.; Casado, A.; Westermann, A.; Isambert, N.; Casali, P.G.; Pratap, S.; Stark, D.;
Valverde, C.; et al. A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in
high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first
line treatment (EORTC62113). Int. J. Gynecol. Cancer 2020, 30, 1633–1637.
83. Hensley, M.L.; Barrette, B.A.; Baumann, K.; Gaffney, D.; Hamilton, A.L.; Kim, J.W.; Maenpaa, J.U.; Pautier, P.; Siddiqui, N.A.;
Westermann, A.M.; et al. Gynecologic Cancer InterGroup (GCIG) consensus review: Uterine and ovarian leiomyosarcomas. Int. J.
Gynecol. Cancer 2014, 24, S61–S66. [CrossRef]
84. Van der Graaf, W.T.; Blay, J.Y.; Chawla, S.P.; Kim, D.W.; Bui-Nguyen, B.; Casali, P.G.; Schöffski, P.; Aglietta, M.; Staddon, A.P.;
Beppu, Y.; et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase
3 trial. Lancet 2012, 379, 1879–1886. [CrossRef]
85. Kobayashi, H.; Uekuri, C.; Akasaka, J.; Ito, F.; Shigemitsu, A.; Koike, N.; Shigetomi, H. The biology of uterine sarcomas: A review
and update. Mol. Clin. Oncol. 2013, 1, 599–609. [CrossRef] [PubMed]
86. Gonzalez Dos Anjos, L.; de Almeida, B.C.; Gomes de Almeida, T.; Mourão Lavorato Rocha, A.; De Nardo Maffazioli, G.; Soares,
F.A.; Werneck da Cunha, I.; Baracat, E.C.; Carvalho, K.C. Could miRNA Signatures be Useful for Predicting Uterine Sarcoma and
Carcinosarcoma Prognosis and Treatment? Cancers 2018, 10, 315. [CrossRef] [PubMed]
87. Kowalewska, M.; Bakula-Zalewska, E.; Chechlinska, M.; Goryca, K.; Nasierowska-Guttmejer, A.; Danska-Bidzinska, A.; Bidzinski,
M. microRNAs in uterine sarcomas and mixed epithelial-mesenchymal uterine tumors: A preliminary report. Tumour Biol. 2013,
34, 2153–2160. [CrossRef]
88. Ravid, Y.; Formanski, M.; Smith, Y.; Reich, R.; Davidson, B. Uterine leiomyosarcoma and endometrial stromal sarcoma have
unique miRNA signatures. Gynecol. Oncol. 2016, 140, 512–517. [CrossRef] [PubMed]
89. De Almeida, B.C.; Dos Anjos, L.G.; Uno, M.; Cunha, I.W.D.; Soares, F.A.; Baiocchi, G.; Baracat, E.C.; Carvalho, K.C. Let-7 miRNA’s
Expression Profile and Its Potential Prognostic Role in Uterine Leiomyosarcoma. Cells 2019, 8, 1452. [CrossRef]
90. De Almeida, B.C.; Garcia, N.; Maffazioli, G.; dos Anjos, L.G.; Baracat, E.C.; Carvalho, K.C. Oncomirs Expression Profiling in
Uterine Leiomyosarcoma Cells. Int. J. Mol. Sci. 2017, 19, 52. [CrossRef] [PubMed]
91. Guled, M.; Pazzaglia, L.; Borze, I.; Mosakhani, N.; Novello, C.; Benassi, M.S.; Knuutila, S. Differentiating soft tissue
leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis. Genes Chromosomes Cancer 2014, 53, 693–702.
[CrossRef] [PubMed]
92. Stope, M.B.; Cernat, V.; Kaul, A.; Diesing, K.; Koensgen, D.; Burchardt, M.; Mustea, A. Functionality of the Tumor Suppressor
microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma. Anticancer Res. 2018, 38, 1547–1550. [PubMed]
93. Berton-Rigaud, D.; Devouassoux-Shisheboran, M.; Ledermann, J.A.; Leitao, M.M.; Powell, M.A.; Poveda, A.; Beale, P.; Glasspool,
R.M.; Creutzberg, C.L.; Harter, P.; et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian
carcinosarcoma. Int. J. Gynecol. Cancer 2014, 24, S55–S60. [CrossRef] [PubMed]
94. Cantrell, L.A.; Blank, S.V.; Duska, L.R. Uterine carcinosarcoma: A review of the literature. Gynecol. Oncol. 2015, 137,
581–588. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 3822 23 of 26
95. Pautier, P.; Floquet, A.; Gladieff, L.; Bompas, E.; Ray-Coquard, I.; Piperno-Neumann, S.; Selle, F.; Guillemet, C.; Weber, B.;
Largillier, R.; et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by
radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French
Sarcoma group. Ann. Oncol. 2013, 24, 1099–1104. [CrossRef]
96. Reed, N.S.; Mangioni, C.; Malmström, H.; Scarfone, G.; Poveda, A.; Pecorelli, S.; Tateo, S.; Franchi, M.; Jobsen, J.J.; Coens, C.; et al.
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and
II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur. J.
Cancer 2008, 44, 808–818. [CrossRef] [PubMed]
97. Omura, G.A.; Major, F.J.; Blessing, J.A.; Sedlacek, T.V.; Thigpen, J.T.; Creasman, W.T.; Zaino, R.J. A randomized study of adriamycin
with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983, 52, 626–632. [CrossRef]
98. Brunetti, M.; Agostini, A.; Staurseth, J.; Davidson, B.; Heim, S.; Micci, F. Molecular characterization of carcinosarcomas arising in
the uterus and ovaries. Oncotarget 2019, 10, 3614–3624. [CrossRef]
99. McConechy, M.K.; Hoang, L.N.; Chui, M.H.; Senz, J.; Yang, W.; Rozenberg, N.; Mackenzie, R.; McAlpine, J.N.; Huntsman, D.G.;
Clarke, B.A.; et al. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. J. Pathol. Clin. Res. 2015,
1, 173–185. [CrossRef] [PubMed]
100. Cherniack, A.D.; Shen, H.; Walter, V.; Stewart, C.; Murray, B.A.; Bowlby, R.; Hu, X.; Ling, S.; Soslow, R.A.; Broaddus, R.R.; et al.
Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell 2017, 31, 411–423. [CrossRef] [PubMed]
101. Tseng, J.H.; Bisogna, M.; Hoang, L.N.; Olvera, N.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Sood, A.K.; Levine, D.A.; Jelinic, P.
miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Sci. Rep. 2017, 7, 3614.
[CrossRef] [PubMed]
102. Miccò, M.; Sala, E.; Lakhman, Y.; Hricak, H.; Vargas, H.A. Imaging Features of Uncommon Gynecologic Cancers. AJR Am. J.
Roentgenol. 2015, 205, 1346–1359. [CrossRef]
103. Olawaiye, A.; Lee, L.M.; Krasner, C.; Horowitz, N. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase
inhibitor Tarceva. Gynecol. Oncol. 2007, 106, 628–630. [CrossRef]
104. Richard, S.D.; Krivak, T.C.; Beriwal, S.; Zorn, K.K. Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.
Int. J. Gynecol. Cancer 2008, 18, 1132–1135. [CrossRef]
105. Plaza, J.A.; Torres-Cabala, C.; Ivan, D.; Prieto, V.G. HER-2/neu expression in extramammary Paget disease: A clinicopatho-
logic and immunohistochemistry study of 47 cases with and without underlying malignancy. J. Cutan. Pathol. 2009, 36,
729–733. [CrossRef]
106. Woelber, L.; Prieske, K.; Eulenburg, C.; Oliveira-Ferrer, L.; de Gregorio, N.; Klapdor, R.; Kalder, M.; Braicu, I.; Fuerst, S.;
Klar, M.; et al. p53 and p16 expression profiles in vulvar cancer: A translational analysis by the Arbeitsgemeinschaft Gynäkolo-
gische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. Am. J. Obstet. Gynecol. 2021. [CrossRef]
107. De Melo Maia, B.; Lavorato-Rocha, A.M.; Rodrigues, L.S.; Coutinho-Camillo, C.M.; Baiocchi, G.; Stiepcich, M.M.; Puga,
R.; de A. Lima, L.; Soares, F.A.; Rocha, R.M. microRNA portraits in human vulvar carcinoma. Cancer Prev. Res. 2013, 6,
1231–1241. [CrossRef]
108. Yang, X.; Wu, X. miRNA expression profile of vulvar squamous cell carcinoma and identification of the oncogenic role of
miR-590-5p. Oncol. Rep. 2016, 35, 398–408. [CrossRef]
109. Yang, S.; Zhao, Y.; Wang, L.; Liu, C.; Lu, Y.; Fang, Z.; Shi, H.; Zhang, W.; Wu, X. MicroRNA-4712-5p promotes proliferation of the
vulvar squamous cell carcinoma cell line A431 by targeting PTEN through the AKT/cyclin D1 signaling pathways. Oncol. Rep.
2019, 42, 1689–1698. [CrossRef]
110. Yang, X.H.; Guo, F. miR-3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression. Mol. Med. Rep. 2018,
17, 6397–6404. [CrossRef] [PubMed]
111. Yuan, G.; Wu, L.; Li, B.; An, J. Primary malignant melanoma of the cervix: Report of 14 cases and review of literature. Oncotarget
2017, 8, 73162–73167. [CrossRef] [PubMed]
112. Min, K.J.; Kim, Y.S.; Hong, J.H.; Lee, J.K.; Yang, D.S. Primary malignant melanoma of uterine cervix: A suggestion of new scheme
of treatment combination. Chin. J. Cancer Res. 2014, 26, 351–354. [PubMed]
113. DiVincenzo, M.; Suarez-Kelly, L.; Moufawad, M.; Ren, C.; Barricklow, Z.; Fadda, P.; Yu, L.; Peters, S.; Gru, A.; Carson, W.
736 MicroRNA expression patterns in melanomas originating from gynecologic sites. J. Immunother. Cancer 2020, 8. [CrossRef]
114. Vergani, E.; Dugo, M.; Cossa, M.; Frigerio, S.; Di Guardo, L.; Gallino, G.; Mattavelli, I.; Vergani, B.; Lalli, L.; Tamborini, E.; et al.
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory
mediators. Cell Commun. Signal. 2020, 18, 156. [CrossRef] [PubMed]
115. Audrito, V.; Serra, S.; Stingi, A.; Orso, F.; Gaudino, F.; Bologna, C.; Neri, F.; Garaffo, G.; Nassini, R.; Baroni, G.; et al. PD-L1 up-
regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget 2017, 28, 15894–15911.
[CrossRef] [PubMed]
116. Ngan, H.Y. The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int. J. Gynecol. Cancer 2004, 14,
202–205. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 3822 24 of 26
117. Steigrad, S.J. Epidemiology of gestational trophoblastic diseases. Best Pract. Res. Clin. Obstet. Gynaecol. 2003, 17,
837–847. [CrossRef]
118. Dhanda, S.; Ramani, S.; Thakur, M. Gestational trophoblastic disease: A multimodality imaging approach with impact on
diagnosis and management. Radiol. Res. Pract. 2014, 2014, 842751. [CrossRef] [PubMed]
119. Nagymanyoki, Z.; Growdon, W.B.; Sarno, J.; Callahan, M.J.; Parast, M.M.; Fulop, V.; Mok, S.C.; Horowitz, N.; Berkowitz, R.S.
Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J. Reprod. Med. 2008, 53,
589–594. [PubMed]
120. Na, Q.; Wang, D.; Song, W. Underexpression of 4 placenta-associated microRNAs in complete hydatidiform moles. Int. J. Gynecol.
Cancer 2012, 22, 1075–1080. [CrossRef] [PubMed]
121. Zhao, J.R.; Cheng, W.W.; Wang, Y.X.; Cai, M.; Wu, W.B.; Zhang, H.J. Identification of microRNA signature in the progression of
gestational trophoblastic disease. Cell Death Dis. 2018, 9, 94. [CrossRef] [PubMed]
122. Lin, L.H.; Maestá, I.; St Laurent, J.D.; Hasselblatt, K.T.; Horowitz, N.S.; Goldstein, D.P.; Quade, B.J.; Sun, S.Y.; Braga, A.;
Fisher, R.A.; et al. Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. Am. J. Obstet.
Gynecol. 2021, 224, 372.e1–372.e30. [CrossRef]
123. Chao, A.; Tsai, C.L.; Wei, P.C.; Hsueh, S.; Chao, A.S.; Wang, C.J.; Tsai, C.N.; Lee, Y.S.; Wang, T.H.; Lai, C.H. Decreased expression
of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett.
2010, 291, 99–107. [CrossRef]
124. Pang, R.T.; Leung, C.O.; Lee, C.L.; Lam, K.K.; Ye, T.M.; Chiu, P.C.; Yeung, W.S. MicroRNA-34a is a tumor suppressor in
choriocarcinoma via regulation of Delta-like1. BMC Cancer 2013, 13, 1–10. [CrossRef]
125. Guo, Z.; Sui, L.; Qi, J.; Sun, Q.; Xu, Y.; Zou, N.; Xie, Y.; Kong, Y. miR-196b inhibits cell migration and invasion through targeting
MAP3K1 in hydatidiform mole. Biomed. Pharmacother. 2019, 113, 108760. [CrossRef] [PubMed]
126. Wang, Y.-X.; Zhao, J.-R.; Xu, Y.-Y.; Wu, W.-B.; Zhang, H.-J. miR-21 Is Overexpressed in Hydatidiform Mole Tissues and Promotes
Proliferation, Migration, and Invasion in Choriocarcinoma Cells. Int. J. Gynecol. Cancer 2017, 27, 364–374. [CrossRef]
127. Palma Flores, C.; García-Vázquez, R.; Gallardo Rincón, D.; Ruiz-García, E.; Astudillo de la Vega, H.; Marchat, L.A.; Salinas
Vera, Y.M.; López-Camarillo, C. MicroRNAs driving invasion and metastasis in ovarian cancer: Opportunities for translational
medicine (Review). Int. J. Oncol. 2017, 50, 1461–1476. [CrossRef] [PubMed]
128. Prahm, K.P.; Novotny, G.W.; Hogdall, C.; Hogdall, E. Current status on microRNAs as biomarkers for ovarian cancer. APMIS
2016, 124, 337–355. [CrossRef]
129. Resnick, K.E.; Alder, H.; Hagan, J.P.; Richardson, D.L.; Croce, C.M.; Cohn, D.E. The detection of differentially expressed
microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 2009, 112,
55–59. [CrossRef]
130. Cortez, M.A.; Bueso-Ramos, C.; Ferdin, J.; Lopez-Berestein, G.; Sood, A.K.; Calin, G.A. MicroRNAs in body fluids—the mix of
hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8, 467–477. [CrossRef]
131. Kim, Y.K. Extracellular microRNAs as Biomarkers in Human Disease. Chonnam Med. J. 2015, 51, 51–57. [CrossRef] [PubMed]
132. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant,
K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008,
105, 10513–10518. [CrossRef]
133. Reid, G.; Kirschner, M.B.; van Zandwijk, N. Circulating microRNAs: Association with disease and potential use as biomarkers.
Crit. Rev. Oncol. Hematol. 2011, 80, 193–208. [CrossRef]
134. Ender, C.; Meister, G. Argonaute proteins at a glance. J. Cell Sci. 2010, 123, 1819–1823. [CrossRef]
135. Iftikhar, H.; Carney, G.E. Evidence and potential in vivo functions for biofluid miRNAs: From expression profiling to functional
testing: Potential roles of extracellular miRNAs as indicators of physiological change and as agents of intercellular information
exchange. Bioessays 2016, 38, 367–378. [CrossRef] [PubMed]
136. Zhang, H.; Xu, S.; Liu, X. MicroRNA profiling of plasma exosomes from patients with ovarian cancer using high-throughput
sequencing. Oncol. Lett. 2019, 17, 5601–5607. [CrossRef] [PubMed]
137. Penyige, A.; Marton, E.; Soltesz, B.; Szilagyi-Bonizs, M.; Poka, R.; Lukacs, J.; Szeles, L.; Nagy, B. Circulating miRNA Profiling in
Plasma Samples of Ovarian Cancer Patients. Int. J. Mol. Sci. 2019, 20, 4533. [CrossRef]
138. Chao, A.; Lai, C.H.; Chen, H.C.; Lin, C.Y.; Tsai, C.L.; Tang, Y.H.; Huang, H.J.; Lin, C.T.; Chen, M.Y.; Huang, K.G.; et al.
Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J. Obstet. Gynecol. 2014, 53, 536–541. [CrossRef] [PubMed]
139. Murray, M.J.; Halsall, D.J.; Hook, C.E.; Williams, D.M.; Nicholson, J.C.; Coleman, N. Identification of microRNAs from the
miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am. J. Clin. Pathol. 2011, 135,
119–125. [CrossRef]
140. Murray, M.J.; Smith, S.; Ward, D.; Verduci, L.; Nicholson, J.C.; Scarpini, C.G.; Coleman, N. Circulating microRNAs as biomarkers
to assist the management of the malignant germ-cell-tumour subtype choriocarcinoma. Transl. Oncol. 2021, 14, 100904. [CrossRef]
141. Yokoi, A.; Matsuzaki, J.; Yamamoto, Y.; Tate, K.; Yoneoka, Y.; Shimizu, H.; Uehara, T.; Ishikawa, M.; Takizawa, S.; Aoki, Y.; et al.
Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma. Cancer Sci. 2019, 110, 3718–3726.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 3822 25 of 26
142. Hasegawa, Y.; Miura, K.; Furuya, K.; Yoshiura, K.; Masuzaki, H. Identification of complete hydatidiform mole pregnancy-
associated microRNAs in plasma. Clin. Chem. 2013, 59, 1410–1412. [CrossRef] [PubMed]
143. Miura, K.; Miura, S.; Yamasaki, K.; Higashijima, A.; Kinoshita, A.; Yoshiura, K.; Masuzaki, H. Identification of pregnancy-
associated microRNAs in maternal plasma. Clin. Chem. 2010, 56, 1767–1771. [CrossRef] [PubMed]
144. Erson-Bensan, A.E. Alternative polyadenylation and RNA-binding proteins. J. Mol. Endocrinol. 2016, 57, F29–F34. [CrossRef]
145. Sandberg, R.; Neilson, J.R.; Sarma, A.; Sharp, P.A.; Burge, C.B. Proliferating cells express mRNAs with shortened 3′ untranslated
regions and fewer microRNA target sites. Science 2008, 320, 1643–1647. [CrossRef]
146. Mayr, C.; Bartel, D.P. Widespread shortening of 3’UTRs by alternative cleavage and polyadenylation activates oncogenes in
cancer cells. Cell 2009, 138, 673–684. [CrossRef] [PubMed]
147. Akman, B.H.; Can, T.; Erson-Bensan, A.E. Estrogen-induced upregulation and 3’-UTR shortening of CDC6. Nucleic Acids Res.
2012, 40, 10679–10688. [CrossRef]
148. Akman, H.B.; Oyken, M.; Tuncer, T.; Can, T.; Erson-Bensan, A.E. 3′UTR shortening and EGF signaling: Implications for breast
cancer. Hum. Mol. Genet. 2015, 24, 6910–6920. [CrossRef]
149. Gruber, A.J.; Zavolan, M. Alternative cleavage and polyadenylation in health and disease. Nat. Rev. Genet. 2019, 20,
599–614. [CrossRef]
150. Singh, P.; Alley, T.L.; Wright, S.M.; Kamdar, S.; Schott, W.; Wilpan, R.Y.; Mills, K.D.; Graber, J.H. Global changes in pro-
cessing of mRNA 3’ untranslated regions characterize clinically distinct cancer subtypes. Cancer Res. 2009, 69, 9422–9430.
[CrossRef] [PubMed]
151. Stricker, T.P.; Brown, C.D.; Bandlamudi, C.; McNerney, M.; Kittler, R.; Montoya, V.; Peterson, A.; Grossman, R.; White, K.P.
Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. PLoS Genet. 2017,
13, e1006589. [CrossRef]
152. Begik, O.; Oyken, M.; Cinkilli Alican, T.; Can, T.; Erson-Bensan, A.E. Alternative Polyadenylation Patterns for Novel Gene
Discovery and Classification in Cancer. Neoplasia 2017, 19, 574–582. [CrossRef] [PubMed]
153. Xue, Z.; Warren, R.L.; Gibb, E.A.; MacMillan, D.; Wong, J.; Chiu, R.; Hammond, S.A.; Yang, C.; Nip, K.M.; Ennis, C.A.; et al.
Recurrent tumor-specific regulation of alternative polyadenylation of cancer-related genes. BMC Genom. 2018, 19, 536. [CrossRef]
154. Chehade, M.; Bullock, M.; Glover, A.; Hutvagner, G.; Sidhu, S. Key MicroRNA’s and Their Targetome in Adrenocortical Cancer.
Cancers 2020, 12, 2198. [CrossRef]
155. Mendonsa, A.M.; Na, T.Y.; Gumbiner, B.M. E-cadherin in contact inhibition and cancer. Oncogene 2018, 37, 4769–4780.
[CrossRef] [PubMed]
156. Vu, T.T.; Stölzel, F.; Wang, K.W.; Röllig, C.; Tursky, M.L.; Molloy, T.J.; Ma, D.D. miR-10a as a therapeutic target and predictive
biomarker for MDM2 inhibition in acute myeloid leukemia. Leukemia 2020. [CrossRef] [PubMed]
157. Jiajie, T.; Yanzhou, Y.; Hoi-Hung, A.C.; Zi-Jiang, C.; Wai-Yee, C. Conserved miR-10 family represses proliferation and induces
apoptosis in ovarian granulosa cells. Sci. Rep. 2017, 7, 41304. [CrossRef] [PubMed]
158. Feng, Y.H.; Tsao, C.J. Emerging role of microRNA-21 in cancer. Biomed. Rep. 2016, 5, 395–402. [CrossRef] [PubMed]
159. Jiang, X.M.; Xiang, G.; Wang, Y.; Zhang, L.; Yang, X.; Cao, L.; Peng, H.; Xue, P.; Chen, D. MicroRNA-590-5p regulates proliferation
and invasion in human hepatocellular carcinoma cells by targeting TGF-β RII. Mol. Cells 2012, 33, 545–551. [CrossRef] [PubMed]
160. Chen, J.; Yao, D.; Li, Y.; Chen, H.; He, C.; Ding, N.; Lu, Y.; Ou, T.; Zhao, S.; Li, L.; et al. Serum microRNA expression levels
can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int. J. Mol. Med. 2013, 32,
557–567. [CrossRef]
161. Stark, M.S.; Tyagi, S.; Nancarrow, D.J.; Boyle, G.M.; Cook, A.L.; Whiteman, D.C.; Parsons, P.G.; Schmidt, C.; Sturm, R.A.; Hayward,
N.K. Characterization of the melanoma miRNAome by deep sequencing. PLoS ONE 2010, 5, e9685. [CrossRef]
162. Wang, F.Y.; Kang, C.S.; Wang-Gou, S.Y.; Huang, C.H.; Feng, C.Y.; Li, X.J. EGFL7 is an intercellular EGFR signal messenger that
plays an oncogenic role in glioma. Cancer Lett. 2017, 384, 9–18. [CrossRef]
163. Huang, C.; Yuan, X.; Wan, Y.; Liu, F.; Chen, X.; Zhan, X.; Li, X. VE-statin/Egfl7 expression in malignant glioma and its relevant
molecular network. Int. J. Clin. Exp. Pathol. 2014, 7, 1022–1031.
164. Hansen, T.F.; Andersen, R.F.; Olsen, D.A.; Sørensen, F.B.; Jakobsen, A. Prognostic importance of circulating epidermal growth
factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. Sci. Rep. 2017, 7,
1–9. [CrossRef]
165. Papaioannou, D.; Shen, C.; Nicolet, D.; McNeil, B.; Bill, M.; Karunasiri, M.; Burke, M.H.; Ozer, H.G.; Yilmaz, S.A.; Zitzer, N.; et al.
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc. Natl. Acad. Sci. USA
2017, 114, E4641–E4647. [CrossRef]
166. Oh, J.; Park, S.H.; Lee, T.S.; Oh, H.K.; Choi, J.H.; Choi, Y.S. High expression of epidermal growth factor-like domain 7 is
correlated with poor differentiation and poor prognosis in patients with epithelial ovarian cancer. J. Gynecol. Oncol. 2014, 25,
334–341. [CrossRef]
167. Yamauchi, M.; Fukuda, T.; Wada, T.; Kawanishi, M.; Imai, K.; Tasaka, R.; Yasui, T.; Sumi, T. Expression of epidermal growth
factor-like domain 7 may be a predictive marker of the effect of neoadjuvant chemotherapy for locally advanced uterine cervical
cancer. Oncol. Lett. 2016, 12, 5183–5189. [CrossRef] [PubMed]
168. Andersen, M.; Trapani, D.; Ravn, J.; Sørensen, J.B.; Andersen, C.B.; Grauslund, M.; Santoni-Rugiu, E. Methylation-associated
Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. Anticancer Res. 2015, 35, 6223–6229.
Int. J. Mol. Sci. 2021, 22, 3822 26 of 26
169. Bommer, G.T.; Gerin, I.; Feng, Y.; Kaczorowski, A.J.; Kuick, R.; Love, R.E.; Zhai, Y.; Giordano, T.J.; Qin, Z.S.; Moore, B.B.; et al.
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17, 1298–1307. [CrossRef] [PubMed]
170. He, L.; He, X.; Lim, L.P.; de Stanchina, E.; Xuan, Z.; Liang, Y.; Xue, W.; Zender, L.; Magnus, J.; Ridzon, D.; et al. A microRNA
component of the p53 tumour suppressor network. Nature 2007, 447, 1130–1134. [CrossRef]
171. Chang, T.C.; Wentzel, E.A.; Kent, O.A.; Ramachandran, K.; Mullendore, M.; Lee, K.H.; Feldmann, G.; Yamakuchi, M.; Ferlito, M.;
Lowenstein, C.J.; et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell.
2007, 26, 745–752. [CrossRef] [PubMed]
172. Bhatia, S.; Kaul, D.; Varma, N. Functional genomics of tumor suppressor miR-196b in T-cell acute lymphoblastic leukemia.
Mol. Cell. Biochem. 2011, 346, 103–116. [CrossRef] [PubMed]
173. Coskun, E.; von der Heide, E.K.; Schlee, C.; Kühnl, A.; Gökbuget, N.; Hoelzer, D.; Hofmann, W.K.; Thiel, E.; Baldus, C.D. The role
of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia.
Leuk. Res. 2011, 35, 208–213. [CrossRef]
174. How, C.; Hui, A.B.; Alajez, N.M.; Shi, W.; Boutros, P.C.; Clarke, B.A.; Yan, R.; Pintilie, M.; Fyles, A.; Hedley, D.W.; et al. MicroRNA-
196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. PLoS ONE 2013, 8, e67846. [CrossRef]
